UNIVERSITI PUTRA MALAYSIA

ANTI-BREAST CANCER EFFECT AND MOLECULAR MECHANISM OF ACTION OF ARTONIN E USING In Silico, In Vitro AND In Vivo APPROACHES

IMAOBONG CHRISTOPHER ETTI

FPV 2016 30

ANTI-BREAST CANCER EFFECT AND MOLECULAR MECHANISM OF ACTION OF ARTONIN E USING *In Silico*, *In Vitro* AND *In Vivo* APPROACHES

By

IMAOBONG CHRISTOPHER ETTI

Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in Fulfillment of the Requirements for the Degree of Doctor of Philosophy

November 2016

Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfillment of the requirement for the Degree of Doctor of Philosophy

ANTI-BREAST CANCER EFFECT AND MOLECULAR MECHANISM OF ACTION OF ARTONIN E USING *In Silico*, *In Vitro* AND *In Vivo* APPROACHES

By

IMAOBONG CHRISTOPHER ETTI

November 2016

Chairman : Professor Rasedee Abdullah, PhD
Faculty : Veterinary Medicine

In spite of advances in medicine, breast cancer still remains a leading cause of death among women worldwide. The resistance and high toxicity ensuing from available modern breast cancer treatment regimens have reduced the survival rate, causing most cancer patients to seek natural remedies with fewer side-effects as alternatives. This study was conducted to investigate the anti-breast cancer effect and elucidate the molecular mechanism of action of Artonin E, a prenylated flavonoid extracted from the stem bark of *Artocarpus elasticus*. The *in silico* anti-cancer effect of Artonin E was evaluated by targeting the human estrogen receptor α (hERα), present in approximately 70% of breast cancers. The Glide, Schrodinger Suite 2015 was used in the molecular docking study. The structure of the ligand binding domain of hERα was retrieved from Protein Data Bank while the structures of compounds were collected from PubChem database and prepared with the Schrodinger Suite. The compounds: Artonin E, Artobiloxanthone, Cycloartocarpesin, Artelastin, Artonin Y, Artonin U, Artonin L, Artonin T, Artonin S, Tamoxifen and the native ligand, were first examined for their drug-likeness before the conduct of the docking study. The cytotoxicity and mode of cell death induced by Artonin E on breast cancer cells were examined *in vitro* using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, acridine orange (AO) and propidium iodide (PI) double staining, annexin V/FITC staining and DNA fragmentation analysis. Caspase-8 and -9 assays, total reactive oxygen species (ROS) assay, apoptosis- and cell cycle-related gene expression, human apoptosis proteome profiling array and Western blot analyses were used to determine the mechanism of apoptosis induced by Artonin E on MCF-7 and MDA-M-231 cells. The regulation of the breast cancer cell cycle was also investigated using flowcytometry. In the *in vivo* study, the mouse 4TI cell-induced mammary gland tumor model was used. The development of the tumor in mice was investigated over the 28 days of bi-weekly oral treatment with Artonin E. Serum biochemical parameters and liver, lung and kidney histopathology of treated mice were analysed. From the docking study, Artonin E had the best glide score among analogues of similar structure from the Artocarpus species and was chosen as a lead for further studies. Artonin E was shown to produce a half-

maximal growth inhibition in MCF-7 cells at concentrations of 6.9, 5.1 and 3.8 µM and in MDA-MB-231 at 14.3, 13.9 and 9.8 µM after 24, 48 and 72 hours of treatment, respectively. The greater cytotoxicity of Artonin E on MCF-7 when compared to MDA-MB-231 cells was confirmed by AO/PI and annexin V-FITC assays, thus, validating its strong binding affinity to the hERα, as shown by the molecular docking studies. Artonin E was less toxic to the normal breast epithelial (MCF 10A) cell line with IC_{50} of 45.80 µM. The morphological analysis and cell viability assay showed that the breast cancer cells treated with Artonin E lost viability and underwent apoptosis. Artonin E induced p53 independent G1 cell cycle arrest and apoptosis through ROS mediated mitochondrial pathway and livin suppression in MCF-7 breast cancer cells. It downregulated anti-apoptotic proteins with a corresponding upregulation of apoptosis inducers and caused a G2/M cell cycle arrest in MDA-MB 231 cells. These observations were evident by the gene expression analysis, caspase assay, ROS assays, apoptosis profiling and Western blot analysis. In the mouse mammary gland tumor model, Artonin E significantly ($p<0.05$) delayed tumor growth and reduced the relative tumor volume in a dose-dependent manner. By histopathological examination, the mammary gland tumor in mice treated with Artonin E showed lesser metastasis in a dose-dependent manner compared to the untreated control. Thus, this study showed that Artonin E has great potential to be developed as an anti-breast cancer agent.

Abstrak tesis yang dikemukakan kepda Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk Ijazah Doktor Falsafah

MEKANISME MOLEKUL KESAN ARTONIN E TERHADAP KANSER PAYUDARA YANG DITENTUKAN MELALUI PENDEKATAN *In Silico*, *In Vitro* AND *In Vivo*

Oleh

IMAOBONG CHRISTOPHER ETTI

November 2016

Pengerusi : Profesor Rasedee Abdullah, PhD
Fakulti : Perubatan Veterinar

Walaupun bidang perubatan kini sudah maju, namum kanser payudara masih kekal sebagai satu daripada penyebab utama kematian wanita di seluruh dunia. Kerentanan dan ketoksikan tinggi akibat daripada penggunaan regim rawatan moden terhadap kanser payudara telah mengurangkan kadar kemandirian, menyebabkan kebanyakan pesakit terpaksa mencari, sebagai ganti, cari rawatan semula jadi yang kurang kesan sampingannya. Kajian ini dijalankan untuk menyelidik mekanisma antikanser payudara Artonin E, suatu flavonoid terprenil yang diestrak daripada kulit batang pokok *Artocarpus elasticus*. Kesan antikanser *in silico* Artonin E dinilai dengan menyasarkan reseptor estrogen α manusia (hERα), yang wujud dalam lebih kurang 70% daripada kanser payudara. Glide, Schrodinger Suite 2015 telah diguna dalam kajian pengedokan molekul. Struktur domain pengikatan ligand pada hERα diperolehi daripada Protein Bank Data. Struktur sebatian diperolehi daripada pangkalan data PubChem dan disedia menggunakan Schrodinger Suite. Sebatian: Artonin E, Y, U, L, T, dan S, Artobiloksanton, Sikloartokarpesin, Artelastin, Tamoksifen dan ligand asli, terlebih dahulu diperiksa keserupaan drugnya sebelum menjalani kajian pengedokan. Kesitoksikan dan mod kematian sel yang diaruh oleh Artonin E terhadap sel kanser payudara dikaji secara *in vitro* dengan menggunakan assai 3-(4,5-dimetiltiazol-2-il)-2,5-difeniltetrazolium bromida (MTT), pewarnaan berganda akridina jingga (AO) and propidium iodida (PI), pewarnaan aneksin V-FITC, dan analisis pemfragmenan DNA. Assai kaspase-8 dan -9 dan spesies oksigen reaktif (ROS) sepenuh, apoptosis dan penyataan gen terkait kitaran sel, profil tatasusunan proteom apoptosis manusia, dan analisis pemendapan Western diguna untuk menentukan mekanisma apoptosis teraruh Artonin E terhadap sel MCF-7 dan MDA-MB-231. Pengawalaturan kitaran sel kanser payudara juga diselidiki mengguna sitometri aliran. Dalam kajian *in vivo* pula, model tumor kelenjar mama mencit teraruh sel 4T1 telah diguna. Perkembangan tumor diselidik dalam mencit terperlaku dua kali seminggu dengan Artonin E pada tempoh 28 hari. Parameter biokimia serum dan histopatologi hati, paru-paru, dan ginjal mencit terawatt dianalisis. Daripada kajian pengedokan, Artonin E menunjukkan skor glide terbaik dikalangan analog berstruktur serupa dengannya yang diperolehi daripada

spesies *Artocarpus* dan dipilih untuk kajian seterusnya. Artonin E telah menghasilkan kadar perencatan pertumbuhan separa maksimum pada kepekatan 6.9, 5.1, dan 3.8 μM untuk sel MCF-7 dan 14.3, 13.9 dan 9.8 μM untuk sel MDA-MB-231, masing-masing selepas 24, 48, dan 72 jam perlakuan. Ketoksikan Artonin E yang lebih tinggi terhadap sel MCF-7 daripada sel MDA-MB-231 telah disahkan melalui assai AO/PI dan aneksin V-FITC dan keafinannya yang tinggi terhadap rERα, seperti yang ditunjukkan melalui kajian pengedokan molekul. Artonin E kurang toksik terhadap jujukan sel (MCF 10A) epitelium payudara normal dengan IC_{50} 45.80 μM. Analisis morfologi dan asai kebolehhidupan menunjukkan yang sel kanser payudara terperlaku Artonin E hilang daya hidupnya dan mengalami apoptosis. Artonin E menyebabkan apoptosis pada sel MCF-7 melalui arah laluan intrinsik manakala pada sel MDA-MB-231 melalui kedua-duanya arah intrinsik dan ekstrinsik. Penemuan ini adalah jelas melalui analisis penyataan gen, assai kaspase dan ROS, dan pemprofilan apoptosis. Artonin E mengaruh penahanan G_0/G_1 pada kitaran sel MCF-7 dan hentian G_2/M pada kitaran sel MDA-MB-231. Dalam model tumor kelanjar mama mencit, Artonin secara ($p<0.05$) tererti melambatkan pertumbuhan dan mengurangkan isipadu tumor secara bersandarkan dos. Melalui pemeriksaan histopatologi, tumor kelenjar mama mencit yang diperlakukan Artonin E, berbanding kawalan tanpa rawatan, kurang kecenderungannya untuk metastasis secara bersandarkan dos. Dengan demikian, kajian ini menunjukkan yang Artonin E mempunyai potensi tinggi untuk dikembangkan sebagai agen antikanser payudara.

ACKNOWLEDGEMENTS

"*Better is the end of a thing than the beginning thereof*" ~Ecclesiastes 7:8 (KJV)~

First and foremost, I am really grateful to the Almighty God, who makes all things beautiful in His time. His divine protection, guidance and sustenance had been the sole foundation of my success.

My unfeigned gratitude goes to my wonderful supervisor, a mentor and a father, Professor Dr. Rasedee Abdullah, who accepted to supervise me at my confused state and guided me with his available resources to a clear and confident end. His unrelenting support and motivation led to the actualization of my dream.

I also express my thanks to my co-supervisors, Dr. Ahmad Bustamam, Assoc. Prof. Dr Arifah Kadir and Dr. Najihah Mohd Hashim, whose unreserved support and unique contributions enabled me to surmount all huddles in the course of my PhD research work.

I am grateful to all members of the Laboratory of Pharmacology, Faculty of Veterinary medicine, the UPM-MAKNA Cancer Research Laboratory, Institute of Bioscience (IBS), and the Immunotherapeutic and Vaccines (LIVES), for their invaluable support in the course of this study. I especially want to thank Dr Yeap Swee Keong for his constant support and guidance during this study.

I also wish to express my appreciation to Dr Mustapha Umar Imam, Dr. Kian Lam Lim, Dr.Dahiru Sani for their support and assistance which had led to the success of this work. I am really grateful to my wonderful group members: Dr Chee Wun, Peter Waziri, Ibrahim Malami, Ms Chaw Yee and Aswaq for all their contributions. My thanks also go to Dr. Mohammed and Masitoh Rahman of the University of Malaya, and my friends, Mitchelle Syling, Han Teh, Careena, Inimfon and Edidiong Udoh.

The support and love of my in-laws, uncles, all my extended family members, my parents, Mr/Mrs Alfred Edet, and siblings, Barr. Kingsley Alfred Edet, Mfonobong Alfred Edet and Ubong Etti, most especially my mother had undoubtedly led to the good landing of this study. I cannot fail to appreciate all the wonderful family members of RCCG, Maranatha covenant chapel and the Lord's Chapel, Malaysia for their prayers and encouragement during this work.

Finally, my heartfelt gratitude goes to my darling husband, Dr. Christopher Etti and precious children, David, Emmanuel and Esther Christopher Etti for their unrelenting support, prayers and encouragement, which led to the success of this research. It is my prayer that the Almighty God will perfect all that concerns you in Jesus Name. Amen.

I certify that a Thesis Examination Committee has met on 22 November 2016 to conduct the final examination of Imaobong Christopher Etti on her thesis entitled "Anti-Breast Cancer Effect and Molecular Mechanism of Action of Artonin E using *In Silico*, *In Vitro* and *In Vivo* Approaches" in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the Doctor of Philosophy.

Members of the Thesis Examination Committee were as follows:

Md Zuki bin Abu Bakar @ Zakaria, PhD
Professor
Institute of Bioscience
Universiti Putra Malaysia
(Chairman)

Latifah binti Saiful Yazan, PhD
Associate Professor
Faculty of Medicine and Health Science
Universiti Putra Malaysia
(Internal Examiner)

Noorjahan Banu binti Mohammed Alitheen, PhD
Associate Professor
Faculty of Biotechnology and Biomolecular Sciences
Universiti Putra Malaysia
(Internal Examiner)

Fang-Rong Chang, PhD
Professor
Kaohsiung Medical University
Taiwan
(External Examiner)

NOR AINI AB. SHUKOR, PhD
Professor and Deputy Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 27 December 2016

This thesis was submitted to the Senate of the Universiti Putra Malaysia and has been accepted as fulfillment of the requirement for the degree of Doctor of Philosophy. The members of the Supervisory Committee were as follows:

Rasedee Abdullah, PhD
Professor
Faculty of Veterinary Medicine
Universiti Putra Malaysia
(Chairman)

Arifah Kadir, PhD
Associate Professor
Faculty of Veterinary Medicine
Universiti Putra Malaysia
(Member)

Ahmad Bustamam Hj Abdul, PhD
Senior Lecturer
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Member)

Najihah Binti Mohd Hashim, PhD
Associate Professor
Faculty of Medicine
Universiti of Malaya
(Member)

ROBIAH BINTI YUNUS, PhD
Professor and Dean
School of Graduate Studies
Universiti Putra Malaysia

Date:

Declaration by graduate student

I hereby confirm that:

- this thesis is my original work;
- quotations, illustrations and citations have been duly referenced;
- this thesis has not been submitted previously or concurrently for any other degree at any institutions;
- intellectual property from the thesis and copyright of thesis are fully-owned by Universiti Putra Malaysia, as according to the Universiti Putra Malaysia (Research) Rules 2012;
- written permission must be obtained from supervisor and the office of Deputy Vice-Chancellor (Research and innovation) before thesis is published (in the form of written, printed or in electronic form) including books, journals, modules, proceedings, popular writings, seminar papers, manuscripts, posters, reports, lecture notes, learning modules or any other materials as stated in the Universiti Putra Malaysia (Research) Rules 2012;
- there is no plagiarism or data falsification/fabrication in the thesis, and scholarly integrity is upheld as according to the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) and the Universiti Putra Malaysia (Research) Rules 2012. The thesis has undergone plagiarism detection software

Signature: _____ Date: 8 / 2/ 2017

Name and Matric No.: Imaobong Christopher Etti / GS 37543

Declaration by Members of Supervisory Committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) were adhered to.

Signature: _____
Name of Chairman of Supervisory Committee: Professor Dr. Rasedee Abdullah

Signature: _____
Name of Member of Supervisory Committee: Associate Professor Dr. Arifah Kadir

Signature: _____
Name of Member of Supervisory Committee: Dr. Ahmad Bustamam Hj Abdul

Signature: _____
Name of Member of Supervisory Committee: Associate Professor Dr. Najihah Binti Mohd Hashim

TABLE OF CONTENTS

LIST OF TABLES

LIST OF FIGURES

LIST OF APPENDICES

LIST OF ABBREVIATIONS

hERα	Human estrogen receptor
ADMET	Absorption, distribution, metabolism and excretion
SDF	Structure-data file
cASTp	Computed Atlas of Surface Topography of proteins
PDB	Protein data bank
LBD	Ligand binding bank
SMAC/ Diablo	Second mitochondria-derived activator of caspases / direct IAP binding protein
TNF	Tumor necrosis factor
TRAIL	Tumor necrosis factor-related apoptosis inducing ligand
HO1/HMOX1/ HSP 32	Heme oxygenase decyclig 1
cIAP-1 & Ciap-2	Cellular inhibitors of apoptosis 1 and 2
IC_{50}	Half-maximal inhibitory concentration
ICAM-1	intercellular Adhesion Molecule 1
xIAP	x-linked inhibitor of apoptosis
S.I	Selectivity index

CHAPTER 1

INTRODUCTION

1.1 Overview

Breast cancer is a complex and heterogeneous disease, constituting an enormous burden to the world at large with increasing mortality rates. It is the most frequently diagnosed cancer and unfortunately the leading cause of cancer death among women (Coughlin and Ekweme, 2009) with an estimated 1.67 million new cases diagnosed in the year 2012 (Ferlay *et al*., 2013). Breast cancer can either be non-invasive, invasive, recurrent or metastatic, with the most common type, constituting approximately 80% of all breast cancers, being the invasive ductal carcinoma (IDC). The development of molecular profiling, has classified breast cancers into five subtypes: luminal A, luminal B, HER2, basal-like and normal-like breast cancers (Perou *et al*., 2000) with each subtype having a different prognosis and treatment response. The luminal types are estrogen receptor-positive with two subtypes, which are human estrogen receptor α and β with the former being implicated in approximately 70% of all breast cancer cases (Berger *et al*., 2012).

Epidemiologic studies have outlined both genetic and non-genetic factors that contribute to the development and progression of breast cancer at all stages. Only between 5 to 10% of breast cancer cases are hereditary. Between 90 to 95% of breast cancer cases are attributed to environmental factors (Easton *et al*., 1993; Anand *et al*., 2008) including age (at menarche, menopause and first pregnancy) (McPherson *et al*., 2000), diet, smoking, and alcohol consumption, (Lin *et al*., 2005), lack of physical activity (Elliassen *et al*., 2006) and the use of oral contraceptives (Althuis, 2003).

Breast cancer survivality is generally lower and resistance to drug therapy is a very common occurrence. The conventional therapeutic strategies in breast cancers include surgery, radiation and chemotherapy (Saxena *et al*., 2012). Due to their limited effectiveness and alarming side effects, there is still a pressing need for the development of alternative anti-breast cancer drugs, especially from natural products that are relatively safe and cheaply available. More than 50% of anticancer drugs approved by the United States Food and Drug Administration have been reported to stem from natural sources (Newman and Cragg, 2016; Dholwani *et al*., 2008).

Artonin E, 5-hydroxy-8,8-dimethyl-3-(3-methylbut-2-enyl)-2-(2,4,5-trihydroxyphenyl) pyrano [2,3-h] chromen-4-one is a prenylated flavonoid compound isolated from the stem bark of *Artocarpus elasticus*, (Rahman *et al*., 2016). The compound has been shown to possess a wide spectrum of *in vitro* biological activities such as antibacterial (Zajmi *et al*., 2015), antimicrobial (Kuete *et al*., 2011), anti-tumor (Rahman *et al*., 2016; Wongpankam *et al*., 2012), anti-migration and anti-invasion (Plaibua *et al*., 2013), antimalarial (Mustapha *et al*., 2010), and other medicinal properties (Suhartati *et al*., 2008: Oonphong *et al*., 2007). However, Artonin E has not been evaluated for its drug-likeness, its molecular interaction with the human estrogen receptor α in breast cancer

cells and the mechanism underlying the anti-breast cancer effect of Artonin E has not yet been reported.

Several approaches and models can be used in the investigation of the anti-breast cancer effect of a compound. Today, with the advancement in computational techniques, *in silico* models can be used to predict the drug-likeness of a promising compound as well as its effect on a target before the conduct of preclinical studies. This study is aimed at the determination of the molecular mechanism of the anti-breast cancer effect of Artonin E utilizing the *in silico*, *in vitro* and *in vivo* approaches.

1.2 Hypothesis

1. Artonin E will have a strong binding affinity to the human estrogen receptor α.
2. Artonin E will effectively inhibit the proliferation of breast cancer cell lines by causing cell death and cell cycle arrest
3. Artonin E will effectively inhibit mice mammary gland tumor growth *in vivo*

1.3 Objectives

The objectives of this study were to determine the:

1. *in silico* pharmacokinetic profile and molecular docking interaction of Artonin E and structural analogues on the human estrogen receptor α.
2. effect of Artonin E on the growth and mode of death of MCF 7 and MDA-MB 231 breast cancer cell lines.
3. regulation of the breast cancer cell cycle and the anticancer mechanisms of cell death induced by Artonin E via gene expression, apoptosis proteome profiling and Western blotting.
4. *in vivo* anticancer activity of Artonin E in a 4T1- mammary gland cancer line-induced mice model.

REFERENCES

Abd-Elzaher, M. M., Labib, A. A., Mousa, H. A., Moustafa, S. A., Ali, M. M., & El-Rashedy, A. A. (2016). Synthesis, anticancer activity and molecular docking study of Schiff base complexes containing thiazole moiety. *Beni-Suef University Journal of Basic and Applied Sciences*, *5*(1), 85–96

Adams, J.M., & Cory, S. (2007). The Bcl-2 apoptotic switch in cancer development and therapy. *Oncogene*, *26*, 1324–1337.

Ahmed, B., Ashfaq, U. A., Ul-Qamar, M. T., & Ahmad, M. (2014). Anticancer potential of phytochemicals against breast cancer: Molecular docking and simulation approach. *Bangladesh Journal of Pharmacology*, *9*(4), 545–550

Alavijeh, M. S., Chishty, M., Qaiser, M. Z., & Palmer, A. M. (2005). Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. *Journal of the American Society for Experimental NeuroTherapeutics, 2*(4), 554–571

Alexandre, J., Batteux, F., Nicco, C., Chereau, C., Laurent, A., Guillevin, L.,Weill, B. & Goldwasser, F. (2006). Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both *in vitro* and *in vivo*. *International Journal of Cancer*, *119*, 41–48.

Ali, S., & Coombes, R. (2000). Estrogen receptor alpha in human breast cancer: occurrence and Significance. *Journal of Mammary Gland Biology and Neoplasia*, *5*(3), 271–281.

Althuis, M. D., Brogan, D. R., Coates, R. D., Darling, J. R., Gammon, M. D., Malone, K. E., Shoenberg, J. B., & Brinton, L. A. (2003). Hormonal content and potency of oral contraceptive breast cancer risk among young women. *British Journal of Cancer*, *1*(88), 50–57.

Altman, R., & Sarg, M. (2000). The Cancer Dictionary. *Checkmark Books*, New York.

Amin, A. R., Kucuk, O., Khuri, F. R., & Shin, D. M. (2009). Perspectives for cancer prevention with natural compounds. *Journal of Clinical Oncology*, *27*(16), 2712–2725.

Anand, P., Kunnumakara, AB., Sundaram, C., Harikumar, K., Tharakan, S.T., Lai, O.S., Sung, B., & Aggarwal, B. (2008). Cancer is a preventable disease that requires major lifestyle changes. *Pharmaceutical Research*, *25*(9), 2097–2116.

Anders, C., Johnson, R., Litton, J., Phillips, M., & Bleyer, A. (2010). Breast cancer before age 40 years. *Seminars in Oncology*, *36*(3), 237–249.

Andruska, N. D., Zheng, X., Yang, X., Mao, C., Cherian, M. M., & Mahapatra, L. (2015). Estrogen receptor α inhibitor activates the unfolded protein response, blocks protein synthesis, and induces tumor regression. *Proceedings of the National Academy of Sciences*, *112*(15), 4737–4742.

Ariazi, E. A., Ariazi, J. L., Cordera, F., & Jordan, V. C. (2006). Estrogen receptors as therapeutic targets in breast cancer. *Current Topics in Medicinal Chemistry*, *6*, 195–216

Armstrong, K, Moye, E., Williams, S., Berlin, J. A., & Reynolds, E.E. (2007). Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians. *Annals of Internal Medicine*, *146*(7), 516–20.

Artandi, S. E., & DePinho, R. (2010). Telomeres and telomerase in cancer. *Carcinogenesis*, *31*, 9–18.

Ashcroft, M., Taya, Y., & Vousden, K. H. (2000). Stress signals utilize multiple pathways to stabilize p53. *Molecular Cell Biology*, *20*, 3224–3233

Aydin, S. (2015). A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA. *Peptides*, *72*, 4–15.

Babiker, F., De Windt, L., Eickels, M., Grohe, C., Meyer, R., & Doevendans, P. (2002). Estrogenic hormone action in the heart: Regulatory network and function. *Cardiovascular Research*, *53*(3), 709–719

Baeriswyl, V., & Christofori, G. (2009). The angiogenic switch in carcinogenesis. *Seminars in Cancer Biology*, *19*, 329–337.

Baliga, M. S., Meleth, S., & Katiyar, S. K. (2005). Growth inhibitory and antimetastatic effect of green tea polyphenols on metastasis-specific mouse mammary carcinoma 4t1 cells in vitro and in vivo systems. *Clinical Cancer Research*, *11*, 1918–1927

Balunas, M., J., & Kinghorn, A. D. (2005). Drug discovery from medicinal plants. *Life Sciences*, *5*(78), 431–441.

Barnes, D. E., & Lindahl, T. (2004). Repair and genetic consequences of endogenous DNA base damage in mammalian cells. *Annual Reviews Genetics*, *38*, 445–476.

Baskić, D., Popović, S., Ristić, P., & Arsenijević, N. (2006). Analysis of cycloheximide-induced apoptosis in human leukocytes: Fluorescence microscopy using annexinV/propidium iodide versus acridine orange/ethidium bromide. *Cell Biology Internatinal*, *30*, 924–932.

Berger, C. E., Qian, Y., Liu, G., Chen, H., & Chen, X. (2012). p53, a target of estrogen receptor (ER) α, modulates DNA damage-induced growth suppression in ER-positive breast cancer cells. *The Journal of Biological Chemistry*, *287*(36), 30117–30127

Bergers, G., & Benjamin, L. E. (2003). Tumorigenesis and the angiogenic switch. *Nature Reviews Cancer*, *3*, 401–410.

Bergström, C. A. S. (2005). *In silico* predictions of drug solubility and permeability: two rate-limiting barriers to oral drug absorption. *Basic and Clinical Pharmacology and Therapeutics*, *96*(3), 156–161

Berthois, Y., Katzenellenbogen, J. A., & Katzenellenbogen, B. S. (1986). Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. *Proceedings of the National Academy of Sciences of the United States of America*, *83*(8), 2496–500.

Bertram, J. S. (2001). The molecular biology of cancer. *Molecular Aspects of Medicine*, *21*, 167–223.

Bertucci, F., & Birnbaum, D. (2008). Reasons for breast cancer heterogeneity. *Journal of Biology*, *7*(2), 6.

Binkowski, T.A., Naghibzadeh, S., and Liang, J. (2003). Computed atlas of surface topography of proteins. Nucleic Acids. *Nucleic Acid Research*, *13*, 3352–3355.

Blasco, M. A. (2005). Telomeres and human disease: Ageing, cancer and beyond. *Nature Review Genetics*, *6*, 611–622.

Bratton, S., & Salvesen, G. (2010). Regulation of the Apaf-1-caspase-9 apoptosome. *Journal of Cell Science*, *123*, 3209–3214.

Brauchle, E., Thude, S., Brucker, S. Y., & Schenke-Layland, K. (2014). Cell death stages in single apoptotic and necrotic cells monitored by Raman microspectroscopy,. *Scientific Reports*, *4*, 4698

Boonphong, S., Baramee, A., & Kittakoop, P. (2007). Antitubercular and antiplasmodial prenylated flavones from the roots of *Artocarpus altilis*. *Chiang Mai Journal of Science*, *34*(3), 339–344.

Boyer, J., Robinson, T., Kutzler, M., Vansant, G., Hokey, D., & Kumar, S. (2007). Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. *Proceedings of the National Academy of Sciences*, *104*, 18648–18653.

Brandenberger, A. W., Tee, M. K., Lee, J. Y., Chao, V., & Jaffe, R. (1997). Tissue distribution of estrogen receptors alpha (ER-alpha) and beta (ER-beta) mRNA in the midgestational human fetus. *The Journal of Clinical Endocrinology and Metabolism*, *2*(87), 3509–3512.

Brooks, B., Brooks, C., Mackerell, A., Nilsson, L., Petrella, R., Roux, B., Won, Y., Archontis, G., Bartels, C., S., Boresch, Caflisch, A., Caves, L., Cui, Q., Dinner, AR., Feig, M., Fischer, S., Gao, J., Hodoscek, M., Im, W., Kuczera, K., Lazaridis, T., Ma, J., Ovchinnikov, V., Paci, E., Pastor, RW., Post, CB., Pu, JZ., Schaefer, M., Tidor, B., Venable, R M., Woodcock, H L., Wu, X., Yang, W., York, MD., Karplus, M. (2009). Charmm: The Biomolecular simulation Program. *Journal of Computational Chemistry*, *30*, 1545–1615.

Burchill. S.A. (2006). What do, can and should we learn from models to evaluate potential anticancer agents? *Future Medicine*, *2*(2), 201–211

Burns, K., & Korach, K. (2012). Estrogen receptors and human disease: an update. *Archives of Toxicology*, *10*, 1491–1504.

Burrell, RA., McGranahan, N., Bartek, J., Swanton, C. (2013). The causes and consequences of genetic heterogeneity in cancer evolution. *Nature*, *7467*(501), 338–45.

Cady, J., & Jackowski, J. (2015). Cancer. In: Brown,D., Edwards, H., Seaton,L. & Buckley,T. (eds.), *in Lewis's Medical Surgical Nursing : Assessment and management of clinical problems* (4th edition, pp. 223–261). Australia: MOSBY, Elsevier.

Cao, R., & Wang, L.-P. (2012). Serological diagnosis of liver metastasis in patients with breast cancer. *Cancer Biology & Medicine*, *9*(1), 57–62

Cardone, MH., Roy, N., Stennicke, HR., Salvesen, GS., Franke, TF., Stanbridge, E., Frisch, S. & Reed, JC. (1998). Regulation of cell death protease caspase-9 by phosphorylation. *Science*, *282*, 1318–1321.

Carlson, RW., Anderson, BO., Bensinger, W., Cox, CE., Davidson, NE., Edge, SB.,Farrar, WB., Goldstein, LJ., Gradishar, WJ., Lichter, AS., McCormick, B., Nabell, LM., Reed, EC., Silver, SM., Smith, ML., Somlo, G., Theriault, R.,Ward, JH., Winer, EP., & Wolff, A. (2000). NCCN practice guidelines for breast cancer. *Oncology*, *11*(14), 33–49.

Carou, M., Cruzans, P., Maruri, A., Stockert, J., & Lombardo, D. (2015). Apoptosis in ovarian granulosa cells of cattle: Morphological features and clearance by homologous phagocytosis. *Acta Histochemica*, *117*(1), 92–103

Central Drug Research Institute (1995). Area antifertility: centchroman phase III drug, trials in advanced cancer of breast. annual report of the central research institute 1994–95. (p. 1). India: Maheshwari & Sons, Lucknow

Celik, L., Lund, J., Schiøtt, B. (2008). Exploring interactions of endocrine-disrupting compounds with different conformations of the human estrogen receptor α ligand binding domain: a molecular docking study. *Chemical Research in Toxicology*, *21*(3), 2195–2206.

Chandna, N., Kumari, K. M., Sharma, C., Vijjulatha, M., Kapoor, J. K., & Sharma, P. K. (2015). QM/MM Docking Strategy and Prime/MM-GBSA calculation of celecoxib analogues as N-myristoyltransferase inhibitors. *Virology & Mycology*, *04*(01).

Chavez, J., Garimella, S., & Lipkowitz, S. (2012). Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. *Breast Disease*, *32*, 35–48.

Chechina, O., Ryazantseva, N., & Novitsky, V. (2011). The proteins of Bcl-2 family are molecular targets of IL-2 and IL-4 apoptotic effects. *Immunology*, *32*, 127–130.

Chen, L., Huang, T., Meseck, M., Mandeli, J., Fallon, J., & Woo, S. (2007). Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with immune stimulation. *Molecular Therapy 15*(12), 2194–2202.

Chen, QR., Vansant, G., Oades, K., Pickering, M.,Wei, J., Song, YK., Monforte, J. & Khan, J. (2007). Diagnosis of the small round blue cell tumors using multiplex polymerase chain reaction. *Journal of Molecular Diagnostics*, *9*, 80–88.

Chen, X., Duan, N., Zhang, C., & Zhang, W. (2016). Survivin and tumorigenesis: molecular mechanisms and therapeutic strategies. *Journal of Cancer*, *7*(3), 314–323

Chiou, W. . (2001). The rate and extent of oral availability versus the rate and extent of oral absorption:clarification and recommendation of terminology. *Journal of Pharmacokinetics and Biopharmaceutics*, *28*, 3–6.

Circu, M. L., & Aw, T. Y. (2010). Reactive oxygen species, cellular redox systems, and apoptosis. *Free Radical Biology and Medicine*, *48*(6), 749–762

Clarke, R., & Johnson, M. (2000). In: Diseases of the Breast. In J. Harris, M. Lippman, M. Morrow, & S. Hellman (Eds.), *Animal models* (pp. 319–333). Philadelphia: Lippincott.

Coates, A. S., Winer, E. P., Goldhirsch, A., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., Thürlimann, B. & Senn, H-J H.-J. (2015). Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015. *Annals of Oncology*, *26*(8), 1533–1546.

Cong, Y., & Shay, J. W. (2008). Actions of human telomerase beyond telomeres. *Cell Research*, *18*, 725–732.

Conklin, K. A. (2000). Dietary Antioxidants During Cancer Chemotherapy: Impact on Chemotherapeutic Effectiveness and Development of Side Effects. *Nutrition and Cancer*, *37*(1), 1–18.

Conklin, K. A. (2004). Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. *Integrative Cancer Therapies*, *3*, 294–300

Corbett, T., Valeriote, F., & LoRusso, P. (1998). Anticancer drug development guide: preclinical screening, clinical trials and approval. In: Teicher B (Ed.), (pp. 75–99.). Totowa, New Jersey: Humana Press, Inc.

Corbett, T., White, K., Polin, L., Kushner, J., Paluch, J., Shih, C., & Grossman, C. (2003). Discovery and preclinical antitumor efficacy evaluations of LY32262 and LY33169. *Investigational New Drugs. 21*, 33–45.

Coughlin, S., & Ewkueme, D. (2009). Breast cancer as a global health concern. *Cancer Epidemiology*, *33*, 315–318.

Couse, J., Lindzey, J., Grandien, K., Gustafsson, J., & Korach, K. S. (1997). Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. *Endocrinology*, *1*(138), 4613–4621.

Cragg, G. M., & Newman, D. J. (2001). *Medicinals for the millenia: the historical record*. *Annals of the New York Academy* 953.

Cross, JB. Thompson, D.C. Rai, B.K. Baber, J.C. Fan, K.Y. & Hu, Y, H. C. (2009). Comparison of several molecular docking programs: pose prediction and virtual screening accuracy. *Journal of Chemical Information and Modelling*, *6*(49), 1455–1474.

Da Rocha, A., Lopes, R. F. & Schwartsmann, G. (2001). Natural products in anticancer therapy. *Current Opinion in Pharmacology*, *1*(4), 364–369.

Dameron, K. M., Volpert, O. V., Tainsky, M. A., & Bouck, N. (1994). Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. *Science*, *265*(5178), 1582–1584.

Daniel, P. T., Koert, U., & Schuppan, J. (2006). Apoptolidin: Induction of apoptosis by a natural product. *Angewandte Chemie International Edition, , 45*, 872–893.

Darvas, F., Keseru, G., Papp, A., Dormán, G., Urge, L., & Krajcsi, P. (2002). *In silico* and *ex silico* ADME approaches for drug discovery. *Topics in Medicinal Chemistry*, *2*, 1287–1304.

Das, D., Koh, Y., Tojo, Y., Ghosh, A.K., Mitsuya, H. (2009). Prediction of potency of protease inhibitors using free energy simulations with polarizable quantum mechanics-based ligand charges and a hybrid water model. *Journal of Chemical Information and Modeling.*, *49*, 2851–2862.

Davies, M. A., & Samuels, Y. (2010). Analysis of the genome to personalize therapy for melanoma. *Oncogene*, *29*, 5545–5555.

De Almeida, E. (2009). Preclinical and clinical studies of laoachol and beta lapachone. *The Open Natural Products Journal*, *2*, 42–47.

DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008). The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. *Cell Metabolism*, *7*, 11–20.

Dehn, D. L., Winski, S. L., & Ross, D. (2004). Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1. *Clinical Cancer Research*, *10*(9), 3147–3155.

DeNardo, D. G., Andreu, P., & Coussens, L. M. (2010). Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. *Cancer Metastasis Review*, *29*, 309–316.

Desai, N., Mahto, M. K., Alekhya, B., Naveen, C. R., & Bhaskar, P. M. (2012). Comparative docking studies of estrogen receptor inhibitors and their binding interaction analysis. *International Journal of Pharmaceutical Sciences Review and Research*, *16*(1), 91–95.

Dasari, S., & Tchounwou, P. B. (2014). Cisplatin in cancer therapy: molecular mechanisms of action. *European Journal of Pharmacology* 740, 364–378.

Degen, W., Pruijn, G., Raats, J., & van Venrooij, W. (2000). Caspase-dependent cleavage of nucleic acids. *Cell Death Differentiation*, *7*, 616–627.

Dholwani, K., Saluja, A., Gupta, A., & Shah, D. (2008). A review on plant-derived natural products and their analogs with anti-tumor activity. *Indian Journal of Pharmacology*, *40*(2), 49–58.

Dickson, M. A., & Schwartz, G. K. (2009). Development of cell-cycle inhibitors for cancer therapy. *Current Oncology*, *16*(2), 36–43.

Diehn, M., Cho, R. W., Lobo, N. A., Kalisky, T., Jo, M., Kulp, A. N., Qian, D., Lam, J.S., Ailles, L. E., Wong, M., Joshua, B., Kaplan, M., Wapnir, I., Dirbas, F., Somlo, G., Paz, B., Shen, J., Lau, S. K., Quake, S. R, Martin, J, Weissman, I., & Clarke, M.F. (2009). Association of Reactive Oxygen Species Levels and Radioresistance in Cancer Stem Cells. *Nature*, *458*(7239), 780–783

DiMasi, Joseph, A., Ronald, W., Hansen, G., & Grabowski, H. (2003). The price of innovation: new estimates of drug development costs. *Journal of Health Economics*, *22*, 151–185.

Dixon, R., & Ferreira, D. (2002). Molecules of interest: Genistein. *Phytochemistry*, *60*, 205–211.

Dubey, K., Ray, A. R., & Behera, B. . (2008). Production of demethylated colchicine from microbial transformation and scale up process development. *Process Biochemistry*, *43*, 251–257.

Dundas, J., Ouyang, Z., Tseng, J., Binkowski, A., Turpaz, Y., & Liang, J. (2006). CASTp: computed atlas of surface topography of proteins with structural and topographical residues. *Nucleic Acids Research*, *34*.

Dykstra, K. D., Guo, L., Birzin, E. T., Chan, W., Yang, Y. T., Hayes, E. C., DaSilva, C. A., Pai, L.Y., Mosley, R.T., Kraker, B., Fitzgerald, P.M.D., DiNinno, F., Rohrer, S.P.,Schaeffer, J.M., Hammond, Milton L., (2007). Estrogen receptor ligands. Part 16: 2-Aryl indoles as highly subtype selective ligands for ERα. *Bioorganic and Medicinal Chemistry Letters*, *17*(8), 2322–2328.

Eastman A. (2004). Cell cycle checkpoints and their impact on anticancer therapeutic strategies. *Journal of Cellular Biochemistry*, *91*, 221–231.

Easton, D. F., Bishop, D. T., Ford, D., & Crockford, G. (1993). Genetic linkage analyses in familial breast and ovarian cancers: Results from 214 families. *American Journal of Human Genetics*, *52*(4), 678–701.

Edinger, A., & Thompson, C. (2004). Death by design: apoptosis, necrosis and autophagy. *Current Opinion in Cell Biology*, *16*(6), 663–9.

Eglon, M., Mcgrath, B., & Brien, T. (2010). Advanced protocols in oxidative stress ii. *business*, *594*(25), 395–408.

Ekins, S., Waller, C., Swaan, P., Cruciai, G., Wrigton, S., & Wikel, J. (2000). Progress in predicting human ADME parameters in silico. *Journal of Pharmacological and Toxicological Methods*, *44*(1), 251–272

Elizabeth, S., Mankoff, D., & Robert, H. (2016). Novel strategies for breast cancer imaging: new imaging agents to guide treatment. *Journal of Nuclear Medicine*, *57*, 69S–74S.

Elliassen, A. H., Golditz, G. A., Rosner, B., Willet, W. C., & Hankinson, S. E. (2006). Adult weight change and risk of postmenopausal breast cancer. *The Jornal of The American Medical Association*, *2*(296), 193–201.

Elmore, S. (2007). Apoptosis: a review of programmed cell death. *Toxicolologic Pathology*, *35*, 495–516.

Emi, M., Kim, R., Tanabe, K., Uchida, Y., & Togo, T. (2005). Targeted therapy against Bcl-2-related proteins in breast cancer cells. *Breast Cancer Reaseach.7*(6), 940–952.

Etti, I., Abdullah, R., Hashim, N., Kadir, A., Abdul, A., Etti, C., Malami, I., Waziri, P., & How, C. (2016). Artonin E and structural analogs from Artocarpus species abrogates estrogen receptor signaling in breast cancer. *Molecules*, *21*(7), 839.

Fadok, V. A., Voelker, D. R., Campbell, P. A., Cohen, J. J., Bratton, G. L., & Henson, P. M. (1992). Exposure of phosphatidylserine on the surface of apototic lymphocytes triggers specific recognition and removal by macrophages. *Journal of Immunology*, *128*, 2207–2216.

Feldman, J. P., & Goldwasser, R. (2009). A mathematical model for tumor volume evaluation using two-dimensions. *Journal of Applied Quantitative Methods*, *4*(4), 455–462.

Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo M, Parkin DM, Forman D, Bray, F.(2013). GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. Available from http://globocan.iarc.fr.,

Fernández, P. L., Jares, P., Rey, M. J., Campo, E., & Cardesa, A. (1998). Cell cycle regulators and their abnormalities in breast cancer. *Molecular Pathology*, *51*(6), 305–309.

Ferreira, L., Dos Santos, R., Oliva, G., & Andricopulo, A. (2015). *Molecular Docking and Structure-Based Drug Design Strategies*. *Molecules* (Vol. 20).

Fesik, F. W. (2005). Promoting apoptosis as a strategy for cancer drug discovery. *Nature Reviews Cancer*, *5*, 876–885.

Festjens, N., Berghe, T., & Vandenabeele, P. (2006). Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. *Biochimica et Biophysica Acta*, *1757*(9-10), 1371–87.

Fischer, U., & Schulze-Osthoff, K. (2005). Apoptosis-based therapies and drug targets. *Cell Death and Differentiation*, *12*, 942–961.

Friedl, P., & Wolf, K. (2003). Tumour-cell invasion and migration:diversity and escape mechanisms. *Nature Review Cancer*, *3*, 362–374.

Friesner, RA., Murphy, RB., Repasky, MP., Frye, LL., Greenwood, JR., Halgren, TA., Sanschagrin, PC., & Mainz, DT (2006). Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein–ligand complexes. *Journal of Medicinal Chemistry*, *49*, 6177–6196.

Fukai, T., Satoh, K., Nomura, T., & Sakagami, H. (2003). Antinephritis and radical scavenging activity of prenylflavonoids. *Fitoterapia*, *74*, 720–724.

Gabrielli, B., Brooks, K., & Pavey, S. (2012). Defective cell cycle checkpoints as targets for anti-cancer therapies. *Frontiers in Pharmacology*, *3,* 1–6.

Ganz, P. A., Kwan, L., Stanton, A. L., Bower, J. E., and Belin, T. R. (2011). Physical and psychosocial recovery in the year after primary treatment of breast Cancer. *Journal of Clinical Oncology*, *9*(29), 1101–1109.

Gao, F., Lv, J., Wang, Y., Fan, R., Li, Q., Zhang, Z., & Wei, L. (2016). Tamoxifen induces hepatotoxicity and changes to hepatocyte morphology at the early stage of endocrinotherapy in mice. *Biomedical Reports*, *4*, 102–106

Gao, Z., Liu, Z., Bi, M. H., Zhang, J. J., Han, Z. Q., Han, X., Wang, H.Y., Sun, G.P. & Liu, H.(2016). Metformin induces apoptosis via a mitochondria-mediated pathway in human breast cancer cells in vitro. *Experimental and Therapeutic Medicine*, *11*(5), 1700–1706

Gatenby, R. A., & Gillies, R. (2004). Why do cancers have high aerobic glycolysis? *Nature Review Cancer*, *4*, 891–899.

Genheden, S., & Ryde, U. (2015). The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. *Expert Opinion*, *10*(5), 449–461.

Gerard, C., & Goldbeter, A. (2011). A skeleton model for the network of cyclin-dependent kinases driving the mammalian cell cycle. *Interface Focus*, *1*(1), 24–35.

Gerl, R., & Vaux, D. L. (2005). Apoptosis in the development and treatment of cancer. *Carcinogenesis*, *26*(2), 263–270.

Gewies, A.(2003). ApoReview: Introduction To Apoptosis. from http://www.celldeath.de/encyclo/aporev/aporev.htm, retrieved June 2016.

Giannini, E., Testa, R., & Savarino, V. (2005). Liver enzyme alteration: a guide for clinicians. *Canadian Medical Association Journal*, *172*(3), 367–379.

Gilmore, A. P. (2005). Anoikis. *Cell Death and Differentiation*, *12*, 1473–1477.

Gilmore, A. P., Metcalfe, A. D., Romer, L. H., & Streuli, C. (2000). Integrin-mediated survival signals regulate the apoptotic function of Bax through its conformation and subcellular localization. *Journal of Cell Biology*, *149*, 431–446.

Goldar, S., Khaniani, M., Derakhshan, S., & Baradaran, B. (2015). Molecular mechanisms of apoptosis and roles in cancer development and treatment. *Asian Pacific Journal of Cancer Prevention*, *16*(6), 2129–2144.

Goldstein, R., Weinberg, R., & Rosenblatt, M. (2010). Of mice and (wo)men: Mouse models of breast cancer metastasis to bone. *Journal of Bone and Mineral Research*, *25*(3), 431–436.

Golstein, P. 1., & Kroemer, G. (2007). Cell death by necrosis: towards a molecular definition. *Trends in Biochemical Sciences*, *32*(1), 37–43.

Gonzalez-Angulo, A., Morales-Vasquez, F., and Hortobagyi, G. (2007). Overview of resistance to systemic therapy in patients with breast cancer. *Advances in Experimental Medicine and Biology.*, *608*, 1–22.

Grivennikov, S. I., Greten, F. R., & Karin, M. (2010). Immunity, inflammation, and cancer. *Cell*, *140*, 883–899.

Guicciardi, M., & Gores, G. (2009). Life and death by death receptors. *FASEB J*ournal *23*, 1625–1637

Hafer, K., Iwamoto, K., & Schiestl, R. (2008). Refinement of the dichlorofluorescein assay for flow cytometric measurement of reactive oxygen species in irradiated and bystander cell populations. *Radiation Research*, *169*(4), 460–468.

Haglund, C., Aleskog, A., Nygren, P., Gullbo, J., Höglund, M., Wickström, M., Larsson, R., & Lindhagen, E. (2012). In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues. *Cancer Chemotherpy and Pharmacology*, *69*(3), 697–707

Hakim, E. H., Achmad, S. A., Juliawaty, L.D., Makmur, L., Syah, Y.M., Aimi, N., K., & Ghisalberti, E. L. (2006). Prenylated flavonoids and related compounds of the Indonesian Artocarpus. (Moraceae). *Journal of Natural Medicines*, *60*, 161–184.

Hamilton, K., Arao, Y., & Korach, K. (2014). Estrogen hormone physiology: Reproductive findings from estrogen receptor mutant mice. *Reproductive Biology*, *14*, 3–8.

Hanahan, D. (2014). Rethinking the war on cancer. *The Lancet*, *383*(9916), 558–563.

Hanahan, D., & Weinberg, R. (2000). The hallmarks of cancer. *Cell*, *100*(1), 57–70.

Hanahan, D., & Weinberg, R. (2011). Hallmarks of cancer: the next generation. *Cell*, *144*(5), 646–74.

Hancock, J. T., Desikan, R., & Neill, S. J. (2001). Role of reactive oxygen species in cell signaling pathways. *Biochemical Society Transactions*, *29*(2), 345–350.

Hartwell, L. H., & Kastan, M. (1982). Plants used against cancer. In: Lawrence, M. (Ed.), *Science*. USA: Quarterman publication.

Hassan, M., Watari, H., Abualmaaty, A., Ohba, Y., & Sakuragi, N. (2014). Apoptosis and molecular targeting therapy in cancer. *BioMed Research International*, *2014*, 1–23

Hashim, N. M., Rahmani, M., Ee, G.C. L., Sukari, M. A., Yahayu, M., Oktima, W., Ali, A. M., & Go, R (2012). Antiproliferative activity of xanthones isolated from Artocarpus obtusus. *Journal of Biomedicine and Biotechnology*, *2012,*1-9

Hengartner, M. (2000). The biochemisstry of apoptosis. *Nature*, *407,* 770–776.

Hepworth, S. J., Leach, M. O., & Doran, S. J. (1999). Dynamics of polymerization in polyacrylamide gel (PAG) dosimeters:(II) modelling oxygen diffusion. *Physics in Medicine and Biology*, *44*, 1875–1884.

Hocker, H. J., Cho, K.-J., Chen, C.-Y., Rambahal, N., Sagineedu, S. R., Shaari, K., Stanslas, J., Hancock, J. F., Gorfe, A. (2013). Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function. *Proceedings of the National Academy of Sciences of the United States of America*, *110*(25), 10201–10206.

Hodes, R. (2001). Molecular targeting of cancer: telomeres as targets. *Proceedings of the National Academy of Sciences*, *98*(14), 7649–7651.

Hodgson J. (2001). ADMET – turning chemicals into drugs. *Nature Biotechnology*, *19*, 722–726.

Hojris, I., Andersen, J., Overgaard, M., & Overgaard, J. (2000). Late treatment-related morbidity in breast cancer patients randomized to postmastectomy radiotherapy and systemic treatment versus systemic treatment alone. *Acta Oncology.*, *39*(3), 355–372.

Holliday, D. L., & Speirs, V. (2011). Choosing the right cell line for breast cancer research. *Breast Cancer Reaseach*, *13*, 215.

Hollingshead, M. G. (2008). Antitumor efficacy testing in rodents. *Journal of the National Cancer Institute*, *100*(21), 1500–1510.

Houghton, P., Morton, C., Tucker, C., Payne, D., Favours, E., Cole, C., Gorlick, R., Kolb, EA., Zhang, W., Lock, R., Carol, H., Tajbakhsh, M., Reynolds, CP., Maris, JM., Courtright, J., Keir, ST., Friedman, HS., Stopford, C., Zeidner, J., Wu, J, & Liu, T. B, M. (2007). The pediatric preclinical testing program: Description of models and early testing results. *Pediatric Blood Cancer.*, *49*, 928–940.

Huang, S.Y. & Zou, X. (2010). Advances and challenges in protein-ligand docking. *International Journal of Molecular Sciences*, *11*, 3016–3034.

Ibrahim, M. Y., Hashim, N. M., Mohan, S., Abdulla, M. A., Kamalidehghan, B., Ghaderian, M., Dehghan, F., Ali, L. Z., Arbab, I. A., Yahayu, M., Lian, G. E., Ahmadipour, F., & Ali, H.M (2014). α-Mangostin from Cratoxylum arborescens demonstrates apoptogenesis in MCF-7 with regulation of NF-kB and Hsp70 protein modulation *in vitro*, and tumor reduction *in vivo*. *Drug Design, Development and Therapy*, *8*, 1629–1647.

Ikushima, H., & Miyazono, K. (2010). TGFbeta signalling: a complex web in cancer progression. *Nature Reviews Cancer*, *10*, 415–424.

Ingolia, N. (2005). Cell cycle: bistability is needed for robust cycling. *Current Biology*, *15*(23), R961–R963.

Inoue, T., Wu, L., Stuart, J., & Maki, C. G. (2005). Control of p53 nuclear accumulation in stressed cells. *FEBS Letters*, *579*(22), 4978–4984.

Irwin J, Lorber DM, M. S., & Wei B, S. B. (2002). Molecular docking and drug discovery. *Nanoscience and Nanotechnology*, *2*, 50–51.

Jacobs, M. (2004). *In silico* tools to aid risk assessment of endocrine disrupting chemicals. *Toxicology*, *205*, 43–53.

Jackson, J. G., Post, S. M., & Lozano, G. (2011). Regulation of tissue and stimulus-specific cell fate decisions by p53 *in vivo*. *Journal of Pathology, .*, *223*, 127–136

Jackson, S. P., & Bartek, J. (2009). The DNA-damage response in human biology and disease. *Nature*, *461*, 1071–1078.

Jagtap, U. B., & Bapat, V. A. (2010). Artocarpus: a review of its traditional uses, phytochemistry and pharmacology. *Journal of Ethnopharmacology*, *129*, 142–166.

Jahanmehr, S. A., Hyde, K., & Geary, C. G. (1987). Simple technique for fluorescence staining of blood cells with acridine orange. *Journal of Clinical Pathology*, *40*, 926–929.

Jamil, S., Lathiff, S. M. A., Abdullah, S. A., Jemaon, N., & Sirat, H. M. (2014). Antimicrobial Flavonoids from Artocarpus anisophyllus Miq and Artocarpus *l*owii King. *Jurnal Teknologi*, *71*(1), 95–99.

Jain, M. V., Paczulla, A. M., Klonisch, T., Dimgba, F. N., Rao, S. B., Roberg, K., Schweizer, F.Lengerke, C., Davoodpour, P., Palicharla, V., Maddika, S., & Los, M. (2013). Interconnections between apoptotic, autophagic and necrotic pathways: Implications for cancer therapy development. *Journal of Cellular and Molecular Medicine*, *17*(1), 12–29.

Jayasinghe, U. L. B., Samarakoon, T. B., Kumarihamy, B. M. M., Hara, N., & Fujimoto, Y. (2008). Four new prenylated flavonoids and xanthones from the root bark of *Artocarpus nobilis*. *Fitoterapia*, *79*(1), 37–41.

Jiang, Q., Zheng, S., & Wang, G. (2013). Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer. *Future Medicinal Chemistry*, *9*

Jiang, X., & Wang, X. (2004). Cytochrome c-mediated apoptosis. *Annual Review of Biochemistry*, *73*, 87–106.

Jin, H. S., & Lee, T. (2006). Cell cycle-dependent expression of cIAP2 at G2/M phase contributes to survival during mitotic cell cycle arrest. *Biochemical Journal*, *399*, 335–342.

Jin, Z., & El-Deiry, W. S. (2005). Overview of cell death signaling pathways. *Cancer Biol Ther*, *4*, 139–63.

Jones, R. G., & Thompson, C. B. (2009). Tumor suppressors and cell metabolism: a recipe for cancer growth. *Genes Development.*, *23*, 537–548.

Jorgensen, W. L., & Duffy, E. M. (2002). Prediction of drug solubility from structure. *Advanced Drug Delivery Reviews*, *54*, 355–366.

Josh, M. ., Pradeep, S., Adarsh, V. K., Amma, Vijayalekshmi, K., Sudha, R., Balachandran, S., Sreejith, M., Jaleel, U.,& Benjamin, S. (2014). *In silico* evidences for the binding of phthalates onto human estrogen receptor α , β subtypes and human estrogen-related receptor γ. *Molecular Simulation*, *40*(5), 408–417

Kaitin, K. L. (2010). Deconstructing the drug development process; the new face of innovation. *Clinical Pharmacology and Therapeutics*, *87*, 356–361.

Kang, M. H., & Reynolds, C. P. (2009). Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. *B. Clin Cancer Res*, *15*, 1126–1132

Kalyaanamoorthy, S., & Chen, Y. P. (2011). Structure-based drug design to augment hit discovery. *Drug Discovery Today*, *16*, 831–839.

Kaminski, G., Friesner, R., Tirado-Rives, J., & Jorgensen, W. (2001). Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. *Journal of Physical Chemistry*, *28*, 6474–6487

Kapetanovic, I. M. (2008). Computer-aided drug discovery and development (CADDD): *In silico*-chemicobiological approach. *Chemico-Biological Interaction*, *171*, 165–176.

Kasibhatla, S., & Tseng, B. (2003). Why target apoptosis in cancer treatment ? *Molecular Cancer Therapeutics 2,* 573–580.

Kaufmann, S. H., & Earnshaw, W. C. (2000).Induction of apoptosis by cancer chemotherapy. *Experimental Cell Research*, *256*, 42–49.

Kroemer, G., & Reed, J. C. (2000). Mitochondrial control of cell death. *Nature Medicine*, *6*(5), 513–519.

Kenis, H., Van Genderen, H., Bennaghmouch, A., Riniaj, H. , Frederik, P., Narula, J., Hofstra, L. & Reutelingsperger, C. (2004). Cell surface-expressed phosphatidylserine and annexin A5 open a novel portal of cell entry. *Journal of Biological Chemistry*, *279*(50), 52623–52629.

Kennedy, T. (1997). Managing the drug discovery/development interface. *Drug Discovery Today*, *2*(10), 436–444.

Key, T. J., & Allen, N. E. (2001). Nutrition and breast cancer. *The Breast*, *10*, 9–13.

Khan, S. A., Yee, K. A., Kaplan, C., & Siddiqui, J. F. (2002). Estrogen receptor expression in normal human breast epithelium is consistent over time. *International Journal of Cancer*, *102*(4), 334–337.

Kim, B., Masuta, C., Matsuura, H., Takahashi, H., & Inukai, T. (2008). Veinal necrosis induced by turnip mosaic virus infection in Arabidopsis is a form of defense response accompanying HR-like cell death. *Molecular Plant-Microbe Interactions*, *21*, 260–268.

Kim, J., & Park, E. J. (2002). Cytotoxic anticancer candidate from natural resources. Current Medicinal Chemistry. *Anticancer Agents*, *2*, 485–537.

Kim, J. B., O'Hare, M. J., & Stein, R. (2004). Models of breast cancer: is merging human and animal models the future? *Breast Cancer Research 6*(1), 22–30

Kim, R., Emi, M., & Tanabe, K. (2007). Cancer immunoediting from immune surveillance to immune escape. *Immunology*, *121*, 1–14.

Kinders, R., Parchment, RE., Ji, J., Kummar, S., Murgo, AJ., Gutierrez, M., Collins, J., Rubinstein, L., Pickeral, O., Steinberg, SM., Yang, S., Hollingshead, M., Chen, A., Helman, L., Wiltrout, R., Simpson, M., Tomaszewski, JE., Doroshow, JH (2007). Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. *Molecular Intervention*, *7*, 325–334.

King, P., & Perry, M. (2001). Hepatotoxicity of Chemotherapy. *The Oncologist*, *6*, 162–176.

Kingston, D. G. . (2007). The shape of things to come; structural and synthetic study of taxane and related compounds. *Phytochemistry*, *68*(14), 1844–1854.

Ko, H. H., Lu, Y. H., Yang, S. Z., Won, S. J., & Lin, C. N. (2005). Cytotoxic prenylflavonoids from *Artocarpus elasticus*. *Journal of Natural Products*, *68*(11), 1692–1695.

Kochummen, K. M., & Go, R. (2000). *In: Seopadmo, E., Saw, L.G. (Eds.)Moraceae. Tree of Sabah and Sarawak. Ampang Press, Kuala Lumpur, Malaysia*.

Köhler, C., Orrenius, S., & Zhivotovsky, B. (2002). Evaluation of caspase activity in apoptotic cells. *Journal of Immunological Methods*, *265*(1-2), 97–110.

Koivunen, M., & Krogsrud, R. (2006). Principles of Immunochemical Techniques Used in Clinical Laboratories. *Laboratory Medicine*, *37*(8), 490–497.

Kops, G., Weaver, B. A., & Cleveland, D. (2005). On the road to cancer: aneuploidy Cancer, and the mitotic checkpoint. *Nature Review Cancer*, *5*(10), 773–785.

Kovalchuk, A., Aladedunye, F., Rodriguez-Juarez, R., Li, D., Thomas, J., Kovalchuk, O., & Przybylski, R. (2013). Novel antioxidants are not toxic to normal tissues but effectively kill cancer cells. *Cancer Biology and Therapy*, 14(10), 907–915

Kroemer, G., El-Deiry, W. S., Golstein, P., Peter, M. E., Vaux, D., Vandenabeele, P., Zhivotovsky, B., Blagosklonny, M. V., Malorni, W., Knight, R. A., Piacentini, M., Nagata, S.,& Melino, G (2005). Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. *Cell Death and Differentiation*, *12*, 1463–1467.

Kroemer, G., & Reed, J. C. (2000). Mitochondrial control of cell death. *Nature Medicine*, *6*(5), 513–519

Kruczynski, A., Colpaert, F., Tarayre, J., Mouillard, P., Fahy, J., & Hill, B. T. (1998). Preclinical in vivo antitumour activity of vinflunine, a novel fluorinated Vinca alkaloid. *Cancer Chemotherapy and Pharmacology*, *41*, 437–447.

Krysko, D. V., Denecker, G., Festjens, N., Gabriels, S., Parthoens, E., D'Herde, & Vandenabeele, P.(2006). Macrophages use different internalization mechanisms to clear apoptotic and necrotic cells. *Cell Death and Differentiation*, *13*, 2011–2022.

Kuete, V. (2010). Potential of Cameroonian plants and derived-products against microbial infections. *Planta Medica*, *76*, 1–13.

Kuete, V., Ango, P.Y., Fotso, G. W, Kapche, G. D., Dzoyem, J. P., Wouking, A.G., Ngadjui, B.T., Abegaz, B. M Abegaz, B. M. (2011). Antimicrobial activities of the methanol extract and compounds from Artocarpus communis (Moraceae). *BMC Complementary and Alternative Medicine*, *11*, 42.

Lacroix, M. (2006). P53 and Breast Cancer, an Update. *Endocrine Related Cancer*, *13*(2), 293–325.

Laurent, A., Nicco, C., Chéreau, C., Goulvestre, C., Alexandre, J., Alves, A., Lévy, E., Goldwasser, F., Panis, Y., Soubrane, O., Weill, B., Batteux, F. (2005). Controlling tumor growth by modulating endogenous production of reactive oxygen species. *Cancer Research*, *65*(3), 948–956.

Lemmon, M. A., & Schlessinger, J. (2010). Cell signaling by receptor tyrosine kinases. *Cell*, *141*, 1117–1134.

Lequin, R. (2005). Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). *Clinical Chemistry*, *51*(12), 2415–2418.

Ley, C., Horsmany, A., & Kristjansen, P. (2007). Early effects of combrestatin A4 disodium phosphate on tumor perfusion and intestinal fluid pressure. *Neoplasia*, *9*, 108–112

Liu, J., & Wang, Z. (2015). Increased oxidative stress as a selective anticancer therapy. *Oxidative Medicine and Cellular Longevity*, *2015*, 1–12.

Li, J., & Yuan, J. (2008). Caspases in apoptosis and beyond. *Oncogene*, *27*, 6194–6206..

Li, X., Li, Y., Cheng, T., Liu, Z., & Wang, R. (2010). Evaluation of the performance of four molecular docking programs on a diverse set of protein-ligand complexes. *Journal of Computational Chemistry*, *11*, 2109–2125.

Li, Z., Li, J., Mo, B., Hu, C., Liu, H., Qi, H., Wang, X. & Xu, J. (2008). Genistein induces G2/M cell cycle arrest via stable activation of ERK1/2 pathway in MDA-MB-231 breast cancer cells. *Cell Biology and Toxicology*, *24*, 401.

Liang, X.-J., Chen, C., Zhao, Y., & Wang, P. C. (2010). Circumventing Tumor Resistance to Chemotherapy by Nanotechnology. *Methods in Molecular Biology*, *596*(1), 467–488.

Liao, C., Sitzmann, M., Pugliese, A., & Nicklaus, M. C. (2011). Software and resources for computational medicinal chemistry. *Future Medicinal Chemistry*, *3*(8), 1057–1085.

Liao,Y., Zou, Y.-Y., Xia, W.-Y., & Hung, M.-C. (2004). Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer. *Cancer Gene Therapy*, *11*(9), 594–602

LigPrep. (2015). version 3.6, Schrödinger, LLC, New York, NY.

Lima, R. T., Martins, L. M., Guimarães, J. E., Sambade, C., & Vasconcelos, M. H. (2004). Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. *Cancer Gene Therapy*, *11*(5), 309–16.

Lin, K.-W., Liu, C.-H., Tu, H.-Y., Ko, H.-H., & Wei, B.-L. (2009). Antioxidant prenylflavonoids from *Artocarpus communis* and *Artocarpus elasticus*. *Food Chemistry*, *115*, 558–562.

Lin, Y., Kikuchi, S., Tamakoshi, K., Wakil, K., Kondo, T., Niya, Y., Yasuya, H., Nishio, S., Suzuki, S., Tokudome, S., Yamamoto, A., Toyoshima, H., & Tamakoshi, A. (2005). Prospective study of alcohol consumption and breast cancer risk in Japanese Women. *International Journal of Cancer*, *5*(116), 779–783.

Lindsay, J., Esposti, M. D., & Gilmore, A. P. (2011). Bcl-2 proteins and mitochondria-Specificity in membrane targeting for death. *Biochimica et Biophysica Acta - Molecular Cell Research*, *1813*(4), 532–539

Lipinski, C. A. (2004). Lead- and drug-like compounds: the rule-of-five revolution. *Drug Discovery Today. Technologies*, *1*(4), 337–41.

Lipinski, C.A, Lombardo, F., Dominy, B.W, & Feeney, P.J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Advanced Drug Delivery Reviews*, *46*, 3–26.

Locksley, R., Killeen, N., & Lenardo, M. (2001). The TNF and TNF receptor superfamilies: integrating mammalian biology. *Cell*, *104*, 487–501.

López-Vallejo, F., Caulfield, T., Martínez-Mayorga, K., Giulianotti, M. A., Houghten, R. A., Nefzi, A., & Medina-Franco, J. L. (2011). Integrating virtual screening and combinatorial chemistry for accelerated drug discovery. *Combinatorial Chemistry and High Throughput Screening*, *14*, 475–487.

Logue, S. E., Elgendy, M., & Martin, S. J. (2009). Expression, purification and use of recombinant annexin V for the detection of apoptotic cells. *Nature Protocols*, *4*, 1383 – 1395

Lowe, S. W., Cepero, E., & Evan, G. (2004). Intrinsic tumour suppression. *Nature*, *432*, 307–315.

Luo, J., Solimini, N. L., & Elledge, S. J. (2009). Principles of cancer therapy: Oncogene and non-oncogene addiction. *Cell*, *136*, 823–837.

Lyne, P.D., Lamb, M.L., Saeh, J. C. (2006). Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. *Journal of Medicinal Chemistry*, *49*, 4805–4808.

Ma, W., Teng, Y., Hua, H., Hou, J., Luo, T. and Jiang, Y. (2013). Upregulation of heat shock protein 27 confers resistance to actinomycin D-induced apoptosis in cancer cells. *The FEBS Journal*, 4612–4624.

Mackay, A., Tamber, N., Fenwick, K., Iravani, M., Grigoriadis, A., Dexter, T., Lord, CJ., Reis-Filho, JS., & Ashworth, A (2009). A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines. *Breast Cancer Research and Treatment*, *118*, 481–498.

Maestro Version 10.4 and Glide Version 6.0. (2015). *Schrödinger, LLC, New York*.

Mahmood, T., & Yang, P. (2012). Western Blot: Technique, theory, and troubleshooting. *North American Journal of Medical Sciences*, *4*(9), 429–434.

Malumbres, M., & Barbacid, M. (2009). Cell cycle, CDKs and cancer: a changing paradigm. *Nature Review Cancer*, *9*, 153–166.

Martin, L.,& Dowsett, M. (2013). BCL-2: A new therapeutic target in estrogen receptor-positive breast cancer? *Cancer Cell*, *24*, 120–129.

Mann, J. (2002). Natural products in cancer chemotherapy, past, present and future. *Nature Reviews Cancer*, *2*, 143–148.

Malami, I., Abdul, A., Abdullah, R., Bt Kassim, N., Waziri, P., & Etti, I. C. (2016). *In silico* Discovery of Potential Uridine-Cytidine Kinase 2 Inhibitors from the Rhizome of Alpinia mutica. *Molecules*, *21*(4), 417.

Malich, G., Markovic, B., & Winder, C. (1997). The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. *Toxicology*, *124*, 179–192.

Mascotti, K., McCullough, J., & Burger, S. R. (2000). HPC viability measurement: trypan blue versus acridine orange and propidium iodide. *Transfusion*, *40*(6), 693–696.

Massague´, J. (2008). TGFb in cancer. *Cell*, *134*, 215–230.

Masutomi, K., Possemato, R., Wong, J.M., Currier, J.L., Tothova, Z., Manola, J.B., Ganesan, S., Lansdorp, P.M., Collins, K., & Hahn, W.C (2005). The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. *Proceedings of the National Academy of Sciences*, *102,* 8222–8227.

McCauley, J., Zivanovic, A., & Skropeta, D. (2013). Bioassays for anticancer activitie. *Methods in Molecular Biology*, *1055*, 191–205.

McDonnell, M., Wang, D., Khan, S. M., Vander Heiden, M. G., & Kelekar, A. (2003). Caspase-9 is activated in a cytochrome c-independent manner early during TNFalpha-induced apoptosis in murine cells. *Cell Death and Differentiation*, *10*(9), 1005–1015.

Mcilwain, D. R., Berger, T., & Mak, T. W. (2016). Caspase functions in cell death and disease. *Cold Spring Harbor Perspectives in Biology*, *24*, 1–29.

McPherson, K., Steel, C. M., & Dixon, J. M. (2000). ABC of breast diseases. Breast cancer-epidemiology, risk factors and genetics. *British Medical Journal*, *321*, 624–628.

Meng, X. Y., Zhang, H.., Mezei, M., & Cui, M. (2011). Molecular docking: A powerful approach for structure-based drug discovery. *Current Computer Aided Drug Design*, *7*, 146–157.

Miller, F., Miller, B., & Heppner, G. (1983). Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. *Invasive Metastasis*, 21–31.

Mingo-Sion, A. M., Marietta, P. M., Koller, E., Wolf, D. M., & Van Den Berg, C. L. (2004). Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells. *Oncogene*, *23*(2), 596–604

Mistry, P., Deacon, K., Mistry, S., Blank, J., & Patel, R. (2004). NF-κB promotes survival during mitotic cell cycle arrest. *Journal of Biological Chemistry*, *279*, 1482–1490.

Mohammed, L., & Sharma, J. (2006). The role of leukotrienes in the pathophysiology of inflammatory disorders: Is there a case for revisiting leukotrienes as therapeutic targets? *Inflammopharmacology*, *14*, 10–16.

Molina-Cruz, A., DeJong, R. J., Ortega, C., Haile, A., Abban, E., Rodrigues, J., Jaramillo-Gutierrez, G., & Barillas-Mury, C. (2012). Some strains of Plasmodium falciparum, a human malaria parasite, evade the complement-like system of Anopheles gambiae mosquitoes. *Proceedings of the National Academy of Sciences*, *109*(28), E1957–E1962.

Moreno-Sanchez, R., Rodriguez-Enriquez, S., Marin-Hernandez, A., & Saavedra, E. (2007). Energy metabolism in tumor cells. *Federation of European Biochemical Societies Journal*, *274*, 1393–1418.

Mori, M., Aizawa, T., Tokoro, M., Miki, T., & Yamori, Y. (2004). Soy isoflavone tablets reduce osteoporosis risk factors and obesity in middle-aged Japanese women. *Clinical and Experimental Pharmacology and Physiology*, *31*, 39–41.

Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *Journal of Immunological Methods.*, *65*, 55–63.

Moungjaroen, J., Nimmannit, U., Callery, P. S., Wang, L., Azad, N., Lipipun, V., Chanvorachote, P., & Rojanasakul, Y. (2006). Reactive oxygen species mediate caspase activation and apoptosis induced by lipoic acid in human lung epithelial cancer cells through Bcl-2 down-regulation. *The Journal of Pharmacology and Experimental Therapeutics*, *319*(3), 1062–1069.

Mustapa, I., Hakim, E., Juliawaty, L., Syah, Y., & Achmad, S. (2010). Prenylated flavones from some Indonesian Artocarpus and their antimalarial properties. *International Journal of Phytomedicines and Related Industries. 2*(2), 157–160.

Nadege, B., Patrick, L.,& Rodrigue, R. (2009). Mitochondria: from bioenergetics to the metabolic regulation of carcinogenesis. *Frontiers in Bioscience*, *14*, 4015–4034.

Nagaraja, G. M., Kaur, P., Neumann, W., Asea, E. E., Bausero, M. A., Multhoff, G., & Asea, A. (2012). Silencing hsp25/hsp27 gene expression augments proteasome activity and increases CD8+ T cell-mediated tumor killing and memory responses. *Cancer Prevention and Research*, *5*(1), 122–137.

Nagata, S., Nagase, H., Kawane, K., Mukae, N., and Fukuyama, H. (2003). Degradation of chromosomal DNA during apoptosis. *Cell Death and Differentiation*, 10: 108-116.

Negrini, S., Gorgoulis, V. G., & Halazonetis, T. D. (2010). Genomic Instability-an evolving hallmark of cancer. *Nature Reviews Molecular Cell Biology*, *11*, 220–228.

Newman, D. J., & Cragg, G. M. (2016). Natural Products as Sources of New Drugs from 1981 to 2014. *Journal of Natural Products*, *79*(3), 629–661.

Nigam, M., Ranjan, V., Srivastava, S., Sharma, R., & Balapure, A. K. (2008). Centchroman induces G0/G1 arrest and caspase-dependent apoptosis involving mitochondrial membrane depolarization in MCF-7 and MDA MB-231 human breast cancer cells. *Life Sciences*, *82*(11-12), 577–90

Nishida, N. (2006). Angiogenesis in cancer. Vascular Health and Risk management, *2*(3), 213–219.

Ntie-Kang, F. (2013). An *in silico* evaluation of the ADMET profile of the StreptomeDB database. *SpringerPlus*, *2*, 353.

Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009). Natural compounds for cancer treatment and prevention. *Pharmacological Research*, *59*(6), 365–378.

Nyberg, P., Xie, L., & Kalluri, R. (2005). Endogenous inhibitors of angiogenesis. *Cancer Research*, *65*, 3967–3979.

Obexer, P., & Ausserlechner, M. (2014). X-linked inhibitor of apoptosis protein – a critical death resistance regulator and therapeutic target for personalized cancer therapy. *Frontiers in Oncology*, *4*, 197.

Obiorah, I. E., Fan, P., & Jordan, V. C. (2014). Breast cancer cell apoptosis with phytoestrogens is dependent on an estrogen-deprived state. *Cancer Prevention Research*, *7*(9), 939–949

Olivier, M., Eeles, R., Hollstein, M., Khan, M., Harris, C., & Hainaut, P. (2002). The IARC TP53 database: New online mutation analysis and recommendations to users. *Human Mutation*, *19*, 607–614.

Onguéné, P. A., Ntie-Kang, F., Mbah, J. A., Lifongo, L. L., Ndom, J. C., Sippl, W., & Mbaze, L. M. (2013). The potential of anti-malarial compounds derived from African medicinal plants, part I: a pharmacological evaluation of alkaloids and terpenoids. *Malaria Journal*, *12*, 449.

Osborne, C., & Brooks, S. (2006). SDS-PAGE and western blotting to detect proteins and glycoproteins of interest in breast cancer research. *Breast Cancer Research Protocol*, *120*, 217–229.

Ouyang, L., Shi, Z., Zhao, S., Wang, F., Zhou, T., Liu, B., & Bao, J. (2012). Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. *Cell Proliferation*, *45*(6), 487–498.

Oonphong, S., Baramee, A., Kittakoop, P., & Puangsombat, P. (2007). Antitubercular and antiplasmodial prenylated flavones from the roots of *Artocarpus altilis*. *Chiang Mai Journal of Science*, *34*, 339–344.

Park, D. J., and Patek, P. Q. (1998). Detergent and enzyme treatment of apoptotic cells for the observation of DNA fragmentation. *BioTechniques*, *24*(4), 558–560

Parte, P., & Kupfer, D. (2005). Oxidation of tamoxifen by human FMO1 andFMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochrome P450s and hemoglobin. *Drug Metabolism and Disposition*, *33*, 1446–1452.

Paterson, S. C., Lim, C. K., & Smith, K. D. (2003). Analysis of the interaction between alpha-1- acid glycoprotein and tamoxifen and its metabolites. *Biomedical Chromatoghraphy*, *17*, 143–148

Paul, S., Sengupta, S., & Bandyopadhyay, T.K., & Bhattacharyya, A. (2012). Stevioside induced ROS-mediated apoptosis through mitochondrial pathway in human breast cancer cell line MCF-7. *Nutrition and Cancer*, *64*(7), 1087–1094

Peach, M. L., Zakharov, A. V, Liu, R., Pugliese, A., Tawa, G., Wallqvist, A., & Nicklaus, M. C. (2012). Computational tools and resources for metabolism-related property predictions: Overview of publicly available (free and commercial) databases and software. *Future Medicinal Chemistry*, *4*, 1907–1932.

Peixoto, R. C. A., Miranda-Vilela, A. L., Filho, J. S., Carneiro, M. L., Oliveira, R. G. S., da Silva, M. O.,Souza,A.R. & Bao, S. N. (2015). Antitumor effect of free rhodium (II) citrate and rhodium (II) citrate-loaded maghemite nanoparticles on mice bearing breast cancer: a systemic toxicity assay. *Tumor Biology*, *36*(5), 3325–3336

Peng, X.-C., Yang, L., Yang, L.-P., Mao, Y.-Q., Yang, H.-S., Liu, J.-Y.,Zhang, D-M., Chen, L.J & Wei, Y.-Q. (2008). Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34-->Ala mutant. *Journal of Experimental & Clinical Cancer Research 27*, 46. 27-46

Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C., Pollack, J R, Ross, D T, Johnsen, H, Akslen, L a, Fluge, O., Pergamenschikov, A. Williams, C., Zhu, S X., Lønning, P E., Børresen-Dale, a L., Brown, P O., & Botstein, D. (2000). Molecular portraits of human breast tumors. *Nature*, *406*(6797), 747–752.

Plaibua, K., Pongrakhananon, V., Chunhacha, P., Sritularak, B., & Chanvorachote, P. (2013). Effects of Artonin E on migration and invasion capabilities of human lung cancer cells. *Anticancer Resaerch*, *33*, 3079–3088.

Pluta, P., Smolewski, P., Pluta, A., Wierzbowska, A., Nejc, D., Piekarski, J., & Jeziorski, A. (2011). Significance of Bax expression in breast cancer patients *Polish Journal of Surgery*, *83*(10), 549–553.

Pozarowski, P., & Darzynkiewicz, Z. (2004). Analysis of cell cycle by flow cytometry. *Methods in Molecular Biology*, *281*, 301–311.

Prat, A., Parker, JS., Karginova, O., Fan, C., Livasy, C., Herschkowitz, JI., He, X., Perou, CM. (2010). Phenotypic and molecular characterization of the claudin- low intrinsic subtype of breast cancer. *Breast Cancer Research*, *12*, 68.

Pulaski, B., Terman, D. S., Khan, S., Muller, E., & Ostrand-Rosenberg, S. (2000). Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse. *Cancer Research*, *60*, 2710–2715.

Pulaski, B., & Ostrand-Rosenberg, S. (2001). Mouse 4T1 breast tumor Model. In J. E. : Coligan, A. M. Kruisbeek, & D. H. Margulies (Eds.), *Current protocol in immunology* (pp. 20.2.1–20.2.16). New York: John Wiley and Sons, Inc.

Qian, B. Z., & Pollard, J. W. (2010). Macrophage diversity enhances tumor progression and metastasis. *Cell*, *141*, 39–51.

QikProp. (2015). Version 4.6. *Schrödinger, LLC, New York*.

Rahman, M. A., Ramli, F., Karimian, H., Dehghan, F., Nordin, N., Mohd Ali, H., Mohd Hashim, N. (2016). Artonin E Induces Apoptosis via Mitochondrial Dysregulation in SKOV-3 Ovarian Cancer Cells. *Plos One*, *11*(3),

Rahman, N. (1997). Evaluation of the sensitivity in vitro of *Plasmodium falciparum* and in vivo of plasmodium chabaudi Malaria to various drugs and their combinations. *The Medical Journal of Malaysia*, *52*, 390–398.

Ramli, F., Rahmani, M., Kassim, N. K., Hashim, N. M., Sukari, M. A., Akim, A. M., & Go, R. (2013). New diprenylated dihyrochalcones from leaves of *Artocarpus elasticus*. *Phytochemistry Letters*, *6*(4), 582–585.

Ray, P. D., Huang, B.-W., & Tsuji, Y. (2012). Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. *Cellular Signalling*, *24*(5), 981–990.

Rayner, B. S., Duong, T. T., Myers, S. J., & Witting, P. . (2006). Protective effect of a synthetic anti-oxidant on neuronal cell apoptosis resulting from experimental hypoxia re-oxygenation injury. *Journal of Neurochemistry*, *97*, 211–221.

Reddy, G. R., Ueda, N., Hada, T., Sackeyfio, A. C., Yamamoto, S., Hano, Y., Aida, M., & Nomura, T. (1991). A prenylflavone, artonin E, as arachidonate 5-lipoxygenase inhibitor. *Biochemical Pharmacology*, *41*(1), 115–118.

Reis-Filho JS, T. A. (2008). Triple negative tumours: a critical review. *Histopathology*, *52*, 108–118.

Richardson, M., Masse, L., Nanny, K., & Sanders, C. (2004). Discrepant views of oncologists and cancer patients on complementary/alternative medicine. *Support Care Cancer*, *12*, 797–804.

Rivera, E., and Gomez, H. (2010). Chemotherapy resistance in metastatic breast cancer: the evolving role of Ixabepilone. *Breast Cancer Research 12* 2.

Rochefort, H., Glondu, M., Sahla, M. E., Platet, N., & Garcia, M. (2003). How to target estrogen receptor-negative breast cancer ? *Endocrine-Related Cancer*, *10*, 261–266.

Rosmaninho, A., Velho, G., Caetenao, M., & Seleros, M. (2012). Breast cancer: 2 case reports. *Brazilian Annals of Dermatology*, *87*(1), 123–126.

Sa, G., Das, T., Banerje, S., & Chakraborty, J. (2010). Curcumin from exortic spice to modern anticancer drug. *Al Meen Journal of Medical Sciences*, *3*, 21–37.

Saelens X, Festjens N, Vande -Walle L, Van- Gurp M, Van-Loo G, V. P. (2004). Toxic proteins released from mitochondria in cell death. *Oncogene*, *23*, 2861–2874.

Saklani, A., & Kutty, S. K. (2008). Plant-derived compounds in clinical trials. *Drug Discovery Today.*, *13*(3), 161–171.

Salgado-Moran, G., Ramirez-Tagle, R., Glossman-Mitnik, D., Ruiz-Nieto, S., Kishore-Deb, P., Bunster, M., & Lobos-Gonzalez, F. (2015). Docking studies of binding of Ethambutol to the C terminal domain of the Arabinosyltransferase mycobacterium tuberculosis. *Virology and Mycology*, *4*, 141.

Salk, J. J., Fox, E. J., & Loeb, L. A. (2010). Mutational heterogeneity in human cancers: origin and consequences. *Annual Review of Pathology*, *5*, 51–75.

Samie, N., Muniandy, S., Kanthimathi, M. S., Haerian, B. S., and Raja Azudin, R. E. (2016). Novel piperazine core compound induces death in human liver cancer cells: possible pharmacological properties. *Scientific Reports*, *6*(October 2015), 24172.

Samuel, T., K., W., Lober, T., Togo, S. H., Zapata, J. M., & Reed, J. (2006). Distinct BIR domains of cIAP1 mediate binding to and ubiquitination of tumor necrosis factor receptor-associated factor 2 and second mitochondrial activator of caspases. *Journal of Biological Chemistry*, *281*, 1080–1090.

Savill, J., & Fadok, V. (2000). Corpse clearance defines the meaning of cell death. *Nature*, *407*(6805), 784–708.

Sawai, H., and Domae, N. (2011). Discrimination between primary necrosis and apoptosis by necrostatin-1 in Annexin V-positive/propidium iodide-negative cells. *Biochemical and Biophysical Research Communication*, *411*, 569–573.

Saxena, N., Hartman, M., Bhoo-Pathy, N., Lim, J. N., Aw, T.-C., Iau, P., Taib, N. A., Lee, S.-C.,Yip, C.-H., & Verkooijen, H. M. (2012). Breast cancer in south East Asia: Comparison of presentation and outcome between a middle income and a high income country. *World Journal of Surgery*, *36*, 2838–2846.

Schluttenhofer, C., Pattanaik, S., Patra, B., & Yuan, L. (2014). Analyses of Catharanthus roseus and Arabidopsis thaliana WRKY Transcription factors reveal involvement in jasmonate signaling. *BMC Genomics*, *15*, 502.

Schrödinger software release 2015, New York.

Seo, E.K., Lee, D., Shin, Y.G., Chai, H.B., Navarro, H.A., Kardono, L.B., Rahman, I., Cordell, G.A., Farnsworth, N.R, Pezzuto, J.M., Kinghorn, A.D., Wani, M.C., & Wall, M.E. (2003). Bioactive prenylated flavonoids from the stem bark of *Artocarpus kemando*. *Archives of Pharmacal Research*, *124-127*(26).

Shah, I. G., & Parsons, D. L. (1991). Human albumin binding of tamoxifen in the presence of a perfluorochemical erythrocyte substitute. *The Journal of Pharmacy and Pharmacology*, *11*(43), 790–793.

Shapiro, G. I., & Harper, J. W. (1999). Anticancer drug targets: cell cycle and checkpoint control. *J. Clin. Invest.*, *104*(12), 1645–1653.

Shay, J.W.,& Wright, W. E. (2000). Hayflick, his limit, and cellular ageing. *Nature Reviews Molecular Cell Biology*, *1*, 72–76.

Shen, Y., Guo, W., Wang, Z., Zhang, Y., Zhong, L., & Zhu, Y. (2013). Protective effects of hydrogen sulfide in hypoxic human umbilical vein endothelial cells: a possible mitochondria-dependent pathway. *International Journal of Molecular Sciences*, *14*, 13093–108.

Shiozaki, E., Chai, J., Rigotti, D., Riedl, S., Li, P., Srinivasula, S.M., Alnemri, E.S., Fairman, R., Shi, Y. (2003). Mechanism of XIAP-mediated inhibition of caspase-9. *Molecular Cell*, *11*(2), 519–527.

Sigal, A., & Rotter, V. (2000). Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. *Cancer Research*, *60*, 6788–6793.

Song, Y., Sun, H., Zhang, A., Yan, G., Han, Y., Wang, X., & Wang, X. (2014). Plant-derived natural products as leads to anti-cancer drugs. *Journal of Medicinal Plant and Herbal Therapy Research*, *2*, 6–15.

Soule, H. D., Vazquez, J., Long, A., Albert, S., & Brennan, M. (1973). A human cell line from a pleural effusion derived from a breast carcinoma. *Journal of National Cancer Institute*, *51*, 1409 1416.

Speirs, C. K., Hwang, M., Kim, S., Li, W., Chang, S., Varki, V., Mitchell, L., Schleicher, S., & Lu, B. (2011). Harnessing the cell death pathway for targeted cancer treatment. *American Journal of Cancer Research*, *1*(1), 43–61.

Sporn, M. B. (1996). The war on cancer. *Lancet*, *347* (9012), 1377–1381.

Storz, G., & Imlay, J. A. (1999). Oxidative stress. *Current Opinion in Microbiology*, *2*, 188- 194.

Subramani, T., Yeap, S. K., Ho, W. Y., Ho, C. L., Osman, C. P., Ismail, N. H., Rahman, N.M.A. & Alitheen, N. B. (2015). Nordamnacanthal potentiates the cytotoxic effects of tamoxifen in human breast cancer cells. *Oncology Letters*, *9*(1), 335–340

Suganya, J., Radha, M., & Naorem, D. L. (2014). In Silico Docking Studies of Selected Flavonoids - Natural Healing Agents against Breast Cancer. *Asian Pacific Journal of Cancer Prevention*, *15*, 8155–8159

Suhartati, T., & Yandri, H. (2008). The bioactivity test of Artonin E from the bark of Artocarpus *Rigida Blume*. *European Journal of Scientific Research*, *23*, 330–337.

Syah, Y. M., Achmad, S. A., Ghisalberti, E. L., Hakim, E. H., & Mujahidin, D. (2004). Two new cytotoxic isoprenylated flavones, Artoindonesianins U and V, from the heartwood of Artocarpus champeden. *Fitoterapia*, *75*(2), 134–40.

Syam, S., Bustamam, A., Abdullah, R., Sukari, M. A., Hashim, N. M., Ghaderian, M., Rahmani, M., Mohan, S., Abdelwahab, S. I., Ali, H. M (2014). α-Mangostin from *Cratoxylum arborescens* demonstrates apoptogenesis in MCF-7 with regulation of NF-??B and Hsp70 protein modulation *in vitro*, and tumor reduction *in vivo*. *Drug Design, Development and Therapy*, *8*, 1629–1647.

Talmadge, J. E., & Fidler, I. J. (2010). AACR centennial series: the biology of cancer metastasis: historical perspective. *Cancer Research*, *70*, 5649–5669.

Tang, H., Li, J., Liu, X., Wang, G., Luo, M., & Deng, H. (2016). Down-regulation of HSP60 Suppresses the Proliferation of Glioblastoma Cells via the ROS/AMPK/mTOR Pathway. *Scientific Reports*, *6*, 28388.

Teicher, B. A. (2006). Tumor models for efficacy determination. *Molecular Cancer Therapeutics*, *5*(10), 2435–2443

Thornberry, N. A., & Lazebnik, Y. (1998). Caspases: enemies within. *Science*, *281*, 1312–1316.

Tomassi, S., Mangia, A., Lacalamita, R., Bellizzi, A., Fedele, V., Chiriatti, A., Paradiso, A. (2007). Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of β- tubulins. *International Journal of Cancer*, *120*, 2078–2085.

Tofzikovskaya, Z., Casey, A., Howe, O., O'Connor, C., & McNamara, M. (2015). *In vitro* evaluation of the cytotoxicity of a folate-modified β-cyclodextrin as a new anti-cancer drug delivery system. *Journal of Inclusion Phenomena and Macrocyclic Chemistry*, *81*(1), 85–94.

Towbin, H., Staehelin, T., & Gordon, J. (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. *Proceedings of the National Academy of Sciences*, *76*(9), 4350–4354.

Trachootham, D., Alexandre, J., & Huang, P. (2009). "Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach. *Nature Reviews Drug Discovery*, *8*, 579–591.

Tseng, T.-H., Chien, M.-H., Lin, W.-L., Wen, Y.-C., Chow, J.-M., Chen, C.-K., Kuo, T-C. & Lee, W.-J. (2016). Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21(WAF1/CIP1) expression. *Environmental Toxicology*.

Turner, J. V., & Agatonovic-Kustrin, S., Glass, B. (2007). Molecular aspects of phytoestrogen selective binding at estrogen receptors. *Journal of Pharmaceutical Sciences.*, *96*(8), 1879–1885.

Tyagi, A. K., Strongly, S., & Human, S. (2002). To arrest or not to G2/M cell-cycle arrest. *Clinical Cancer Research*, *8*, 3311–3314.

Vaillant, F., Merino, D., Lee, L., Breslin, K., Pal, B., Ritchie, M. E., Smyth, G.K., Christie, M.,Phillipson, L.J.,Christopher, J. &Lindeman, G. (2013). Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. *Cancer Cell*, *24*, 120–129.

Van-Loo, G., Saelens, X., van-Gurp, M., MacFarlane, M., Martin, S., & Vandenabeele, P. (2002). The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. *Cell Death and Differentiation*, *9*(10), 1031–1042.

Varfolomeev, E., Goncharov, T., Fedorova, A., Dynek, J., Zobel, K., Deshayes, K., Fairbrother, W.J., & Vucic, D. (2008). c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. *Journal of Biological Chemistry*, *283*, 24295–24299.

Veber, D. F., Stephen, R., Johnson, H., Cheng, B., Smith, K. W., & Kenneth, D. K. (2002). Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. *Journal of Medicinal Chemistry*, *12*(45), 2615–2623.

Veeresham, C. (2012). Natural products derived from plants as a source of drugs. *Journal of Advanced Pharmaceutical Technology andResearch*, *4*(200-201).

Vermes, I., Haanen, C., Steffens-Nakken, H., & Reutelingsperger, C. (1995). A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. *Journal of Immunological Methods*, *184*(1), 39–51.

Vermeulen, K., Van, B. D. R., & Berneman, Z. (2003). The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. *Cell Proliferation*, *36*(3), 131–49.

Vijayakumar, B., Umamaheswari, A., Puratchikody, A., & Velmurugan, D. (2011). Selection of an improved HDAC8 inhibitor through structure-based drug design. *Bioinformation*, *7*(3), 134–41

Vince, J., Wong, W., Khan, N., Feltham, R., Chau, D., Ahmed, A., Benetatos, C.A., Chunduru, S.K.,Condon, S.M., McKinlay, M., Brink, R., Leverkus, M., Tergaonkar, V.,Schneider, P., Callus, BA.,Koentgen, F.,Vaux, DL. & Silke, J. (2007). IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. *Cell*, *131*, 682–693.

Voskoglou-Nomikos, T., Pater, J., & Seymour, L. (2003). Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. *Clinical Cancer Research*, *9*(11), 4227–4239.

Wafa, K., & Pasumarthi, K. B. (2015). Endogenous and Pharmacological Inhibitors of Cyclin Dependent Kinases in Cell Cycle Regulation of Normal and Cancer Cells. *Austin Journal of Pharmacology and Therapeutics*, *3*(1), 1067.

Waterbeemd, H., & Gifford, E. (2003). ADMET in silico modelling: towards prediction paradise? *Nature Reviews. Drug Discovery*, *2*(3), 192–204

Wang, F., Gao, Y., Gao, L., & Xing, T. (2011). Study on electrochemical behaviour of the anticancer herbal drug, berberine and its analytical application. *Journal of Chinese Chemical Society*, *58*.

Wang, J. (2009). Comprehensive Assessment of ADMET Risks in drug discovery. *Current Pharmaceutical Design*, *15*, 2195–2219.

Wang, Y., Hou, A., Chen, L., Chen, D., Sun, H., Zhao, QS., Bastow, K., Nakanish, Y., Wang, XH., & Lee, KH. (2004). New isoprenylated flavones, artochamins A--E, and cytotoxic principles from Artocarpus chama. *Journal of Natural Product*, *5*, 757–761.

Waring, M. J., Arrowsmith, J., Leach, A., Leeson, P. D., Mandrell, S., Owen, R.M., Pairaudeau, G., Pennie, W.D., Pickett, S.D., Wang, J., Wallace, O., & Wei, A. (2015). An analysis of the attrition of drug candidates from four major pharmaceutical companies. *Nature Reviews Drug Discovery*, *14*, 475–486.

Weiser, M. J., Foradori, C. D., & Handa, R. J. (2008). Estrogen receptor beta in the brain: from form to function. *Brain Research Reviews*, *57*(2), 309–320.

Weng, J. R., Chan, S. C., Lu, Y. H., Lin, H. C., Ko, H. H., & Lin, C. N. (2006). Antiplatelet prenylflavonoids from Artocarpus communis. *Phytochemistry*, *67*, 824–829.

World Health Organisation, Global health estimates. (2013). available at http://www.who.int/cancer/detection/breastcancer/en/index1.html.

Widyawaruyanti, A., Kalauni, S.K., Awale, S., Nindatu, M, Zaini, N., Sya- fruddin, D., Asih,, P.B.S., Tezuka, Y., & Kadota, S.(2007). New prenylated flavones from *Artocarpus champeden* and their antimalarial activity in vitro. *Journal of Natural Medicines*, *61*, 410–413.

Witte, I., Altenhöfer, S., Wilgenbus, P., Amort, J., Clement, A. M., Pautz, A., Li, H., Förstermann, U., & Horke, S. (2011). Beyond reduction of atherosclerosis: PON2 provides apoptosis resistance and stabilizes tumor cells. *Cell Death & Disease*, *2*,112.

Wong, C. W., Song, C., Grimes, M. M., Fu, W., Dewhirst, M. W., Muschel, R. J., & Al-Mehdi, A.-B. (2002). Intravascular location of breast cancer cells after spontaneous metastasis to the lung. *The American Journal of Pathology*, *161*(3), 749–753

Wongpankam, E., Chunhacha, P., & Pongrakhananon, V. (2012). Artonin E Mediates MCL1Down-regulation and Sensitizes Lung Cancer Cells to Anoikis. *Anticancer Research*, *32*, 5343–5351.

World Health Organisation. (2003). World health classification of tumors: T*umors of the breast and female genital organs*. Oxford [Oxfordshire]: Oxford University Press,

World Health Organisation. *World Malaria Report*; WHO technical report: Geneva, 2010.http://www.who.int/malaria/world_malaria_report_2010/worldmalariareport2010.pdf

Wu, B., Li, W., Qian, C., Zhou, Z., Xu, W., & Wu, J. (2012). Down-regulated P53 by siRNA increases Smad4's activity in promoting cell apoptosis in MCF-7 cells. *European Review for Medical and Pharmacological Sciences*, *16*(9), 1243–1248.

Wu, D., & Yotnda, P. (2011). Production and detection of reactive oxygen species (ROS) in cancers. *Journal of Visualised Experiment*, *21*(57), 3357.

Wu, J. (2015). Statistical inference for tumor growth inhibition t/c ratio. *Journaln of Biopharmaceutical Statistics*, *20:*(5), 954–64.

Würstle, M., Laussmann, M., & Rehm, M. (2012). The central role of initiator caspase-9 in apoptosis signal transduction and the regulation of its activation and activity on the apoptosome. *Experimental Cell Research*, *11*, 1213–1220.

Yaghmaie, F., Saeed, O., Garan, S. A., Freitag, W., Timiras, P. S., & Sternberg, H. (2005). Caloric restriction reduces cell loss and maintains estrogen receptor-alpha immunoreactivity in the pre-optic hypothalamus of female B6D2F1 mice. *Neuroendocrinology Letters*, *26*(3), 197–203.

Yamamoto, S., Ueda, N., Hada, T., & Horie, T. (1990). Flavonoids as 5-lipoxygenase inhibitors. In N. Das (Ed.), *In: Flaoonoids in Biology and Medicine III: Current Issues in Flaoonoid Research* (pp. 435–446). National University of Singapore.

Yan H, Dobbie Z, Gruber SB, Markowitz S, R. K., & FM, G. (2002). Small changes in expression affect predisposition to tumorigenesis. *Nature Genetics*, *30*, 25–26.

Yang, Y. L., Lin, S. R., Chen, J. S., Lin, S. W., Yu, S. L., Chen, H. Y., Yen, C.T., Lin, C.Y., Lin, J.F.,Lin, K.H., Jou, S.T., Hu, C.Y., Chang, S.K., Lu, M.Y., Chang, H.H., Chang, W.H., Lin, K.S., & Lin, D.T. (2010). Expression and prognostic significance of the apoptotic genes BCL2L13, Livin, and CASP8AP2 in childhood acute lymphoblastic leukemia. *Leukemia Research*, *34*(1), 18–23.

Yap, D., Hsieh, J. K., Zhong, S., Heath, V., Gusterson, B., Crook, T., & Lu, X. (2004). Ser392 Phosphorylation Regulates the Oncogenic Function of Mutant p53. *Cancer Research*, *64*(14), 17–20.

Yeung, M. C. (2002). Accelerated apoptotic DNA laddering protocol. *BioTechniques*, *33*(4), 734–736.

Ying, QU, Bingchen, H., Yu, Yi., Yao, W., Shikha, R, Beth, K.Y., Armando, A. E., Cui, X. (2015). Evaluation of MCF10A as a reliable model for normal human mammary epithelial cells. *PLoS ONE*, *10*(7), 1–16.

Yonou, H., Yokose, T., & Kamijo, T. (2001). Establishment of a novel species and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human lung and bone. *Cancer Research*, *61*, 2177–2182.

Yu, H. (2000). Role of the insulin-like growth factor family in cancer development and progression. *Journal of the National Cancer Institute*, *92*(18), 1472–1489.

Yuan, J. (2006). Divergence from a dedicated cellular suicide mechanism: exploring the evolution of cell death. *Molecular Cell*, *23*(1), 1–12.

Yuriev, E., Agostino, M., & Ramsland, P. A. (2011). Challenges and advances in computational docking: Review, 2009. *Journal of Molecular Recognition*, *24*, 149–64.

Zajmi A., Hashim, N., Noordin, K., SAM., K., Ramli, F., Mohd, A., & El-Seedi H. (2015). Ultrastructural Study on the Antibacterial Activity of Artonin E versus Streptomycin against Staphylococcus aureus Strains. *PLoS ONE*, *10*(6).

Zhai, J. W., Gao, C., Ma, W. D., Wang, W., Yao, L. P., Xia, X., Luo, M., Zu, Y.G., & Fu, Y.J. (2016). Geraniin induces apoptosis of human breast cancer cells MCF-7 via ROS-mediated stimulation of p38 MAPK. *Toxicology Mechanisms and Methods*, *26*(5), 311–318

Zhang, D., Luo, G., Ding, X., & Chuang, L. (2012). Preclinical experimental models of drug metabolism and disposition in drug discovery and development. *Acta Pharmaceutica Sinica B*, *2*(6), 549–561.

Zhang, J. H., & Xu, M. (2000). DNA fragmentation in apoptosis. *Cell Research*, *10*(3), 205–211.

Zhang, X., Giuliano, M. T., Meghana, V., Schiff, R. O., & Osborne, C. (2013). Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer. *Clinical Cancer Research*, *19*(23), 6389–6397.

Zhang, Y., Yang, C., Wang, W., Liu, J., Liu, Q., Huang, F., Chu, L., Gao, H., Li, C., Kong, D., Liu, Q., & Liu, J. (2016). Co-delivery of doxorubicin and curcumin by pH-sensitive prodrug nanoparticle for combination therapy of cancer. *Scientific Reports*, *6*, 2125

Zhao, T., Yan, G.-R., Pan, S.-L., Wang, H.-Y., & Hou, A.-J. (2009). New isoprenylated 2-arylbenzofurans and pancreatic lipase inhibitory constituents from Artocarpus nitidus. *Chemistry and Biodiversity*, *6*, 2209–2216.

Zheng, L., Ren, J. Q., Li, H., Kong, Z. L., & Zhu, H. G. (2004). Downregulation of wild-type p53 protein by HER-2/neu mediated PI3K pathway activation in human breast cancer cells: its effect on cell proliferation and implication for therapy. *Cell Research*, *14*, 497–506.

Zou, P., Zhang, J., Xia, Y., Kanchana, K., & Guo, G. (2014). ROS generation mediates the anti- cancer effects of WZ35 via activating JNK and ER stress apoptotic pathways in gastric cancer. *Oncotarget*, *6*(8).